<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Clin Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">J Exp Clin Cancer Res</journal-id><journal-title-group><journal-title>Journal of Experimental &#x00026; Clinical Cancer Research : CR</journal-title></journal-title-group><issn pub-type="ppub">0392-9078</issn><issn pub-type="epub">1756-9966</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">31906986</article-id><article-id pub-id-type="pmc">PMC6945774</article-id>
<article-id pub-id-type="publisher-id">1503</article-id><article-id pub-id-type="doi">10.1186/s13046-019-1503-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>RETRACTED ARTICLE: Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jin</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1636-6499</contrib-id><name><surname>Guo</surname><given-names>Jiwei</given-names></name><address><email>guojiwei0510@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Weiwei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lijuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaohong</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Kaikai</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Juanjuan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Miao</surname><given-names>Shuang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xuelin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Guoming</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008w1vb37</institution-id><institution-id institution-id-type="GRID">grid.440653.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9588 091X</institution-id><institution>Clinical Medicine Laboratory, </institution><institution>Binzhou Medical University Hospital, </institution></institution-wrap>Binzhou, 256603 People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008w1vb37</institution-id><institution-id institution-id-type="GRID">grid.440653.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9588 091X</institution-id><institution>Cancer research institute, </institution><institution>Binzhou Medical University Hospital, </institution></institution-wrap>Binzhou, 256603 People&#x02019;s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008w1vb37</institution-id><institution-id institution-id-type="GRID">grid.440653.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9588 091X</institution-id><institution>Department of Thyroid and Breast Surgery, </institution><institution>Binzhou Medical University Hospital, </institution></institution-wrap>Binzhou, 256603 People&#x02019;s Republic of China </aff><aff id="Aff4"><label>4</label>Department of Nursing, Binzhou Polytechnic University, Binzhou, 256603 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>39</volume><elocation-id>6</elocation-id><history><date date-type="received"><day>8</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2020</copyright-statement><copyright-year>2020</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Recent evidence indicates that metformin inhibits mammalian cancer growth and metastasis through the regulation of microRNAs. Metformin regulates miR-381 stability, which plays a vital role in tumor progression. Moreover, increased YAP expression and activity induce non-small cell lung cancer (NSCLC) tumor growth and metastasis. However, the molecular mechanism underpinning how metformin-induced upregulation of miR-381 directly targets YAP or its interactions with the epithelial-mesenchymal transition (EMT) marker protein Snail in NSCLC is still unknown.</p></sec><sec><title>Methods</title><p id="Par2">Levels of RNA and protein were analyzed using qPCR, western blotting and immunofluorescence staining. Cellular proliferation was detected using a CCK8 assay. Cell migration and invasion were analyzed using wound healing and transwell assays. Promoter activity and transcription were investigated using the luciferase reporter assay. Chromatin immunoprecipitation was used to detect the binding of YAP to the promoter of Snail. The interaction between miR-381 and the 3&#x02032;UTR of YAP mRNA was analyzed using the MS2 expression system and co-immunoprecipitation with biotin.</p></sec><sec><title>Results</title><p id="Par3">We observed that miR-381 expression is negatively correlated with YAP expression and plays an opposite role to YAP in the regulation of cellular proliferation, invasion, migration, and EMT of NSCLC cells. The miR-381 function as a tumor suppressor was significantly downregulated in lung cancer tissue specimens and cell lines, which decreased the expression of its direct target YAP. In addition, metformin decreased cell growth, migration, invasion, and EMT via up-regulation of miR-381. Moreover, YAP, which functions as a co-transcription factor, enhanced NSCLC progression and metastasis by upregulation of Snail. Snail knockdown downregulated the mesenchymal marker vimentin and upregulated the epithelial marker E-cadherin in lung cancer cells. Furthermore, miR-381, YAP, and Snail constitute the miR-381-YAP-Snail signal axis, which is repressed by metformin, and enhances cancer cell invasiveness by directly regulating EMT.</p></sec><sec><title>Conclusions</title><p id="Par4">Metformin-induced repression of miR-381-YAP-Snail axis activity disrupts NSCLC growth and metastasis. Thus, we believe that the miR-381-YAP-Snail signal axis may be a suitable diagnostic marker and a potential therapeutic target for lung cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Metformin</kwd><kwd>miR-381</kwd><kwd>YAP</kwd><kwd>Snail</kwd><kwd>EMT</kwd><kwd>NSCLC</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31801085</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Jiwei</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007129</institution-id><institution>Natural Science Foundation of Shandong Province</institution></institution-wrap></funding-source><award-id>ZR2018QH004</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Jiwei</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014103</institution-id><institution>Key Technology Research and Development Program of Shandong</institution></institution-wrap></funding-source><award-id>2019GSF108174</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Jiwei</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Italian National Cancer Institute &#x02018;Regina Elena&#x02019; 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par14">Lung cancer is the leading cause of cancer-associated deaths worldwide. Approximately 80&#x02013;85% of lung cancers are non-small cell lung cancers (NSCLCs), which are classified as adenocarcinomas, lung squamous cell carcinomas, and large-cell carcinomas. Despite the availability of multiple NSCLC clinical treatment options, such as surgery, chemotherapy, and radiotherapy, NSCLC prognosis is still very poor with a five-year survival rate less than 20%, which is mainly attributed to diagnosis at advanced stage, distant metastasis, and drug resistance. Consequently, effective treatment targets and therapies that improve the outcomes of NSCLC patients remain to be explored.</p><p id="Par15">Metformin is a first-line drug for the treatment of type 2 diabetes mellitus. It lowers blood glucose predominantly by promoting insulin sensitivity, glucose uptake into peripheral tissues, and hepatic gluconeogenesis reduction. In recent years, the potential anti-cancer effect of metformin was reported in many cancer types, including NSCLC. There are two mechanisms associated with the anticancer effects of metformin: metformin lowers circulating insulin, which can bind to the highly expressed insulin receptor in cancer cells, thereby indirectly decreasing cell proliferation [<xref ref-type="bibr" rid="CR1">1</xref>]; and metformin directly activates AMPK and subsequently inhibits mammalian target of mTOR, leading to reduced cancer-cell proliferation [<xref ref-type="bibr" rid="CR2">2</xref>]. Recent studies demonstrated that AMPK activation induces Yes-associated protein (YAP) phosphorylation and inhibits YAP transcriptional activity [<xref ref-type="bibr" rid="CR3">3</xref>]. Additionally, LATS1/2 can be activated by an AMPK-dependent pathway to suppress YAP activity by phosphorylating YAP at S127, leading to the retention of YAP in the cytoplasm and the promotion of its degradation [<xref ref-type="bibr" rid="CR3">3</xref>]. In addition, our previous study indicated that metformin downregulates YAP by interfering with interferon regulatory factor 1 (IRF-1) binding to the <italic>YAP</italic> promoter, inhibiting NSCLC growth and metastasis [<xref ref-type="bibr" rid="CR4">4</xref>]. Moreover, several studies showed that the use of metformin was associated with a lower risk of lung cancer among patients with diabetes and improved survival of NSCLC patients with diabetes [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, growing evidence indicates that metformin inhibits mammalian cancer growth and metastasis through regulation of microRNAs (miRNAs). For example, metformin prevents liver tumorigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma [<xref ref-type="bibr" rid="CR8">8</xref>]; The treatment also suppresses melanoma cell growth and motility through modulation of miRNAs expression [<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, metformin disrupts the metastasis associated lung adenocarcinoma transcript&#x000a0;1 (MALAT1)/miR-142-3p sponge, decreasing the invasion and migration of cervical cancer cells [<xref ref-type="bibr" rid="CR10">10</xref>]. However, whether other regulatory mechanisms underpin the effects of metformin in NSCLC, such as metformin-decreased YAP activity by miRNAs regulation, is currently unclear.</p><p id="Par16">microRNAs (miRNAs), a cluster of endogenous small non-coding RNAs, play significant roles in multiple physiological and pathological processes, which maturation process includes catalysis, cleavage, and transport, resulting in three miRNA stages: pri-miRNA (1&#x02013;3&#x02009;k&#x02009;bp), pre-miRNA (60&#x02013;70&#x02009;bp), and mature miRNA (19&#x02013;22&#x02009;bp). The miRNAs biogenesis occurs in the nucleus and their effect is exerted in the cytoplasm. Here they cleave specific target mRNAs or repress the translation by binding to the 3&#x02032; untranslated region (UTR) of specific mRNAs with complementary sequences [<xref ref-type="bibr" rid="CR11">11</xref>]. Emerging evidence indicates that miRNAs have important regulatory effects in tumorigenicity and tumor progression, therefore being used as biomarkers for cancer diagnosis and prognosis as well as therapeutic targets. miR-381 has been reported to exert a tumor-suppressing role in various cancer types such breast [<xref ref-type="bibr" rid="CR12">12</xref>], pancreatic [<xref ref-type="bibr" rid="CR13">13</xref>], cervical [<xref ref-type="bibr" rid="CR14">14</xref>], and gastric [<xref ref-type="bibr" rid="CR15">15</xref>] cancers. It can also repressed cell proliferation, invasion, and migration of epithelial ovarian cancer cells [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, miR-381 overexpression inhibited xenograft growth in a nude mouse model of human pancreatic cancer [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the underlying mechanism through which metformin-regulated miR-381 modulates these cellular processes has not been fully elucidated.</p><p id="Par17">The transcriptional coactivator YAP is the crucial downstream effector of the Hippo signaling pathway, which plays important roles in organ size control, regeneration, and cancer [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. This pathway is highly evolutionarily conserved. The main components of the mammalian MST-YAP signaling pathway are Mst1/2, LATS1/2, and YAP/TAZ. Following activation of the MST-YAP signaling pathway, Mst1/2, as the core component of this kinase chain, is activated and phosphorylates a component downstream of LATS1/2. LATS1/2 mainly inhibits proliferation and migration of tumor cells by blocking cell cycle progression and plays an important regulatory role in cell apoptosis. LATS1/2 phosphorylates YAP/TAZ, which inhibits YAP activity [<xref ref-type="bibr" rid="CR19">19</xref>]. The Hippo pathway, with a kinase cascade at its core, phosphorylates and inactivates YAP, leading to its sequestration or degradation in the cytoplasm by binding to 14&#x02013;3-3 proteins or recruiting E3 ligase Skp Cullin F-box (SCF) &#x003b2;-TrCP [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. When this pathway is inhibited, unphosphorylated YAP translocates into the nucleus and interacts with other transcription factors, mainly TEA domain transcription factors (TEADs), to turn on target gene expression, resulting in tissue overgrowth and tumorigenesis. Mounting evidence suggests that aberrant YAP expression or activity are involved in carcinogenesis, cancer progression, and metastasis in diverse types of cancer [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. However, the regulatory mechanism of the Hippo signaling pathway, especially the regulatory mechanism of YAP at the level of transcription, remains unclear.</p><p id="Par18">Epithelial-mesenchymal transition (EMT) is a process by which epithelial cells acquire a mesenchymal phenotype with enhanced migratory and invasive abilities, accompanied by loss of cell polarity and cell-cell adhesion. EMT is a critical step in the cascade of events leading to cancer metastasis, which contributes to the majority of cancer-associated deaths, and is regulated by a set of transcription factors that include <italic>snail family transcriptional repressor 1</italic> (Snail), <italic>snail family transcriptional repressor 2</italic> (Slug), <italic>zinc finger E-box binding homeobox&#x000a0;1</italic> (ZEB1), and <italic>wist family bHLH transcription factor 1</italic> (Twist) [<xref ref-type="bibr" rid="CR23">23</xref>]. Snail suppresses the transcription of E-cadherin, an epithelial biomarker required for epithelial formation and maintenance, and drives EMT in a variety of human cancers [<xref ref-type="bibr" rid="CR24">24</xref>]. It was reported that Snail expression was significantly elevated in metastatic lesions of ovarian carcinoma [<xref ref-type="bibr" rid="CR25">25</xref>] and knockdown of Snail could reverse EMT and repress tumor growth and invasiveness [<xref ref-type="bibr" rid="CR26">26</xref>]. Accordingly, targeting Snail, and thereby interfering with EMT and further preventing metastasis, may represent a potential cancer therapy strategy. However, regulation of cancer cell EMT and metastasis by the miR-381/YAP axis was not reported in NSCLC. Therefore, in the current study, the molecular mechanism underpinning how metformin-induced upregulation of miR-381 directly targets YAP or its interactions with the epithelial-mesenchymal transition (EMT) marker protein Snail in NSCLC was explored.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Molecular biology</title><p id="Par19">Myc-tagged YAP constructs were made using the pcDNA 3.1 vector (Invitrogen, Carlsbad, CA, USA). Sequences encoding the Myc epitope (EQKLISEEDL) were added by PCR through replacement of the first Met-encoding codon in the respective cDNA clones.</p></sec><sec id="Sec4"><title>Cell lines and culture</title><p id="Par20">Human lung normal cell line HBEC and NSCLC cell lines A549, H1299, Calu6 and H520 were purchased from American Type Culture Collections (Manassas, VA). 95-D cells were purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Science (Shanghai, China). Cell lines were cultivated in RPMI-1640 medium supplemented with 10% FBS (Hyclone, USA), penicillin/streptomycin (100&#x02009;mg/mL). Culture flasks were kept at 37&#x02009;&#x000b0;C in a humid incubator with 5% CO<sub>2</sub>.</p></sec><sec id="Sec5"><title>Over-expression and knockdown of genes</title><p id="Par21">Overexpressing plasmids (2&#x02009;&#x003bc;g) or siRNAs (1.5&#x02009;&#x003bc;g) of indicated genes were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for over-expression and knockdown of indicated genes, followed by analysis 36&#x02009;h later. The selected sequences for knockdown as follow:</p><p id="Par22">siYAP-1 were: 5&#x02032;-GGUGAUACUAUCAACCAAA-3&#x02032;.</p><p id="Par23">siYAP-2 were 5&#x02032;-GACATCTTCTGGTCAGAGA-3&#x02032;.</p><p id="Par24">siSnail-1 were: 5&#x02032;- AGUUUAUUGAUAUUCAAUA-3&#x02032;.</p><p id="Par25">siSnail-2 were: 5&#x02032;-UGGUUAAUUUAUAUACU-3&#x02032;.</p><p id="Par26">siNC were: 5&#x02032;-UUCUCCGAACGUGUCACGU-3&#x02032;.</p></sec><sec id="Sec6"><title>Transfection of miRNA</title><p id="Par27">The miR-381 mimics, miR-381 inhibitors and another scramble oligonucleotide (negative control, NC) were synthesized by GenePharma biotechnology (Shanghai, China). The miRNAs (50&#x02009;nM) transfection was performed with lipofectamine 2000 reagent (Invitrogen) in HBEC, A549 and 95-D cells for 36&#x02009;h, according to the manufacturer&#x02019;s instruction. The sequences of miR-381 mimics, miR-381 inhibitors and scramble oligonucleotide as follow:</p><p id="Par28">miR-381 mimics: 5&#x02032;-UAUACAAGGGCAAGCUCUCUGU-3&#x02032;.</p><p id="Par29">miR-381 inhibitors: 5&#x02032;- ACAGAGAGCUUGCCCUUGUAUA-3&#x02032;.</p><p id="Par30">miR-381 mimics NC: 5&#x02032;- UUGUACUACACAAAAGUACUG-3&#x02032;.</p><p id="Par31">miR-381 inhibitors NC: 5&#x02032;- CAGUACUUUUGUGUAGUACAA-3&#x02032;.</p></sec><sec id="Sec7"><title>RNA isolation and reverse transcription (RT)-PCR assay</title><p id="Par32">We used TRIzol reagent (TransGen Biotech, Beijing, China) to isolate total RNA from the samples. RNA was reverse transcribed into first-strand cDNA using a TransScript All-in-One First-Strand cDNA Synthesis Kit (TransGen Biotech). cDNAs were used in RT-PCR and RT-qPCR assay with the human GAPDH gene as an internal control. The final RT-qPCR reaction mix contained 10&#x02009;&#x003bc;L Bestar&#x000ae; SYBR Green qPCR Master Mix, Amplification was performed as follows: a denaturation step at 94&#x02009;&#x000b0;C for 5&#x02009;min, followed by 40&#x02009;cycles of amplification at 94&#x02009;&#x000b0;C for 30&#x02009;s, 58&#x02009;&#x000b0;C for 30&#x02009;s and 72&#x02009;&#x000b0;C for 30&#x02009;s. The reaction was stopped at 25&#x02009;&#x000b0;C for 5&#x02009;min. The relative expression levels were detected and analyzed by ABI Prism 7900HT / FAST (Applied Biosystems, USA) based on the formula of 2<sup>-&#x00394;&#x00394;ct</sup>. We got the images of RT-PCR by Image Lab&#x02122; Software (ChemiDocTM XRS+, BiO-RAD) and these images were TIF with reversal color format. The RT-PCR primers were:</p><p id="Par33">YAP forward primer: 5&#x02032;-GGATTTCTGCCTTCCCTGAA-3&#x02032;.</p><p id="Par34">YAP reverse primer: 5&#x02032;-GATAGCAGGGCGTGAGGAAC-3&#x02032;.</p><p id="Par35">CTGF forward primer: 5&#x02032;-ACCGACTGGAAGACACGTTTG-3&#x02032;.</p><p id="Par36">CTGF reverse primer: 5&#x02032;-CCAGGTCAGCTTCGCAAGG-3&#x02032;.</p><p id="Par37">Cyr61 forward primer: 5&#x02032;-GGTCAAAGTTACCGGGCAGT-3&#x02032;.</p><p id="Par38">Cyr61 reverse primer: 5&#x02032;-GGAGGCATCGAATCCCAGC-3&#x02032;.</p><p id="Par39">Snail forward primer: 5&#x02032;-TACAAAAACCCACGCAGACA-3&#x02032;.</p><p id="Par40">Snail reverse primer: 5&#x02032;-ACCCCACATCCTTCTCACTG-3&#x02032;.</p><p id="Par41">E-cadherin forward primer: 5&#x02032;-ACCATTAACAGGAACACAGG &#x02212;&#x02009;3&#x02032;.</p><p id="Par42">E-cadherin reverse primer: 5&#x02032;-CAGTCACTTTCAGTGTGGTG-3&#x02032;.</p><p id="Par43">Vimentin forward primer: 5&#x02032;-CGCCAACTACATCGACAAGGTGC-3&#x02032;.</p><p id="Par44">Vimentin reverse primer: 5&#x02032;-CTGGTCCACCTGCCGGCGCAG-3&#x02032;.</p><p id="Par45">GAPDH forward primer: 5&#x02032;-CTCCTCCTGTTCGACAGTCAGC-3&#x02032;.</p><p id="Par46">GAPDH reverse primer: 5&#x02032;-CCCAATACGACCAAATCCGTT-3&#x02032;.</p></sec><sec id="Sec8"><title>In situ hybridization</title><p id="Par47">NSCLC tumor cells were seeded on glass coverslips, fixed with 4% paraformaldehyde for 15&#x02009;min, washed with PBS, and permeabilized with 0.5% Triton X-100 (Biosharp, China) for 10&#x02009;min at room temperature. The slides were then processed using a RiboTM Fluorescent In Situ Hybridization Kit (RiboBio, China). The corresponding FISH Probe Mix was also designed by RiboBio Co. The experiment was repeated three times in A549 cells. Images were obtained with a Zeiss Axio Imager Z1 Fluorescent Microscope (Zeiss, Oberkochen, Germany).</p></sec><sec id="Sec9"><title>MTT and CCK8 assays</title><p id="Par48">To assess the cellular viability and growth, 5&#x02009;&#x000d7;&#x02009;10<sup>4</sup> HBEC and NSCLC tumor cells were seeded onto 6-well plates with transfection of the relevant plasmids. Cell viability and growth were respectively determined using CCK8 and MTT assays in 96-well plates in a manner. Cells were transfected with the relevant plasmids culturing for 36&#x02009;h, followed by incubation with CCK8 for 4&#x02009;h. For MTT assay, MTT solution (5&#x02009;mg/mL, Sigma, st. Louis, MO) of 5&#x02009;&#x003bc;L was added to each well for another 4&#x02009;h. The medium was removed and 100&#x02009;&#x003bc;L DMSO was added into per well to oscillate for 10&#x02009;min. Absorbance was read at 450&#x02009;nm for CCK8 and 570&#x02009;nm for MTT assay using a spectrophotometer (Tecan, M&#x000e4;nnedorf, Switzerland). Cell viability (%)&#x02009;=&#x02009;OD (<italic>treated cells</italic>)/OD (<italic>control cells</italic>)&#x02009;&#x000d7;&#x02009;100.</p></sec><sec id="Sec10"><title>Western blot analysis</title><p id="Par49">Human lung cancer cells were transfected with the relevant plasmids and cultured for 36&#x02009;h. For western blot analysis, the cells were lysed with NP-40 buffer (10&#x02009;mM Tris pH&#x02009;7.4, 150&#x02009;mM NaCl, 1% Triton X-100, 1&#x02009;mM EDTA pH&#x02009;8.0, 1&#x02009;mM EGTA pH&#x02009;8.0, 1&#x02009;mM PMSF, and 0.5% NP-40) containing proteinase and phosphatase inhibitor cocktails (Sigma-Aldrich) at 4&#x02009;&#x000b0;C for 40&#x02009;min. Following centrifugation at 12,000&#x02009;rpm for 15&#x02009;min at 4&#x02009;&#x000b0;C, the supernatant was collected, and protein concentration was determined by BCA assay. Equal protein from the samples were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto nitrocellulose membranes (Millipore, Bredford, MA, USA). The membranes were blocked with 5% skim milk and then probed with corresponding primary antibodies. Following incubation with an HRP-conjugated secondary antibody (Beyotime), immonoreactive signals were detected using by Enhanced chemiluminescence (ECL) technique (Millipore). Tubulin was detected for equal loading control. The primary antibodies used in this study were 1:1000 Abcam (Cambridge, UK) antibody of anti-YAP (ab52771), anti-pYAP (ab62751), anti-CTGF (ab6992) and anti-Cyr61 (ab24448), anti-Ki67 (ab16667), anti-Snail (ab53519), anti-Vimentin (ab45939), anti-E-cadherin (ab1416), anti-cleaved Capase-3 (ab32042) and anti-Tubulin (ab6046).</p></sec><sec id="Sec11"><title>Colony formation assay</title><p id="Par50">The cells (200 cells/well) were inoculated into 6-well plates and cultured for 14&#x02009;days. And then the cells were stained with 0.1% crystal violet. Colonies of more than 50 cells were counted by optical microscope (BX53, Olympus Corporation, Japan), and colony formation capacity was expressed by colony number/inoculated cell number &#x000d7;&#x02009;100%.</p></sec><sec id="Sec12"><title>Wound healing assays</title><p id="Par51">To assess the cellular migration, 10<sup>4</sup> HBEC, A549 and 95-D cells were seeded onto 6-well plates with transfection of the relevant plasmids. These were then incubated in 5% CO<sub>2</sub> at 37&#x02009;&#x000b0;C for 48&#x02009;h. A wound was scraped into the cells using a plastic 200&#x02009;&#x003bc;L tip and then washed by PBS. The cells were then incubated in RPMI-1640 medium containing 2% FBS. Images were captured at the time points of 0 and 36&#x02009;h after wounding. The relative distance of the scratches was observed under an optical microscope (IX53, Olympus, Tokyo, Japan) and assessed using the ImageJ software.</p></sec><sec id="Sec13"><title>Transwell migration assays</title><p id="Par52">Transwell migration assays were performed using a 24-well chamber (Costar 3422; Corning Inc., Corning, NY, USA). The lower and upper chambers were partitioned by a polycarbonate membrane (8-&#x003bc;m pore size). Lung cancer cells (5&#x02009;&#x000d7;&#x02009;10<sup>3</sup>) were seeded into RPMI-1640 without FBS in the upper chamber. RPMI-1640 containing 10% FBS was added to the lower chamber. The cells were allowed to migrate for 36&#x02009;h at 37&#x02009;&#x000b0;C in a humidified atmosphere containing 5% CO<sub>2</sub>. Cells remaining on the upper side of the membrane were removed using PBS-soaked cotton swabs. The membrane was then fixed in 4% paraformaldehyde for 20&#x02009;min at 37&#x02009;&#x000b0;C and then stained with crystal violet. The number of randomly selected cells on the lower side of the membrane were counted under an Olympus light microscope (Olympus, Tokyo, Japan). The cells in the 5 non-repeating field was randomly selected and counted.</p></sec><sec id="Sec14"><title>Immunofluorescent staining</title><p id="Par53">To examine the protein expression and location by immunofluorescent staining, normal lung cell and lung cancer cells were seeded onto coverslips in a 24-well plate and left overnight. Cells were then fixed using 4% formaldehyde for 30&#x02009;min at 25&#x02009;&#x000b0;C and treated with 2% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 30&#x02009;min. The coverslips were incubated with rabbit anti-YAP, Ki67, Annexin V, Snail, Vimentin and mouse anti-E-cadherin monoclonal antibody (Abcam) at 1:200 dilution in 3% BSA at 4&#x02009;&#x000b0;C for overnight. Following incubation with Alexa-Fluor 467 (green, 1:500, A-11029; Invitrogen, USA) and 594 (red, 1:500, A-11032; Invitrogen, USA) tagged anti-rabbit or -mouse monoclonal secondary antibody in 3% BSA. Hoechst (3&#x02009;&#x003bc;g/mL, cat. no. E607328; Sangon Biotech Co., Ltd.) was added for nuclear counterstaining. Images were obtained with a Zeiss Axio Imager Z1 Fluorescent Microscope (Zeiss, Oberkochen, Germany).</p></sec><sec id="Sec15"><title>Analysis of publicly available datasets</title><p id="Par54">To analyze correlation between miR-381 or YAP expression level and prognostic outcome of patients, Kaplan-Meier survival curves of NSCLC patients with low and high expression of miR-381 or YAP were generated using Kaplan-Meier Plotter (<ext-link ext-link-type="uri" xlink:href="http://www.kmplot.com/analysis">www.kmplot.com/analysis</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.oncolnc.org">www.oncolnc.org</ext-link>) [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec16"><title>Subcellular fraction</title><p id="Par55">Transfected A549 cells were harvest in PBS and resuspended for 10&#x02009;min on ice in 500&#x02009;&#x003bc;L CLB Buffer (10&#x02009;mM Hepes, 10&#x02009;mM NaCl, 1&#x02009;mM KH<sub>2</sub>PO<sub>4</sub>, 5&#x02009;mM NaHCO<sub>3</sub>, 5&#x02009;mM EDTA, 1&#x02009;mM CaCl<sub>2</sub>, 0.5&#x02009;mM MgCl<sub>2</sub>). Thereafter, 50&#x02009;&#x003bc;L of 2.5&#x02009;M sucrose was added to restore isotonic conditions. The first round of centrifugation was performed at 6300&#x02009;g for 5&#x02009;min at 4&#x02009;&#x000b0;C. The pellet washed with TSE buffer (10&#x02009;mM Tris, 300&#x02009;mM sucrose, 1&#x02009;mM EDTA, 0.1% NP40, PH 7.5) at 1000&#x02009;g for 5&#x02009;min at 4&#x02009;&#x000b0;C until the supernatant was clear. The resulting pellets were nucleus. The resulting supernatant from the first round was transferred and subjected to centrifugation at 14000&#x02009;rpm for 30&#x02009;min. The resulting pellets were membranes and the supernatant were cytoplasm.</p></sec><sec id="Sec17"><title>Luciferase reporter assay</title><p id="Par56">To construct the core region of Snail promoters, the indicated promoters of Snail was amplified by PCR from the human genomic DNA of A549 cells and were inserted into the upstream of the pGL3-Basic vector (Promega, Madison, WI, USA) via KpnI and XhoI sites to generate Snail luc. Thereafter, we use the Firefly Luciferase Reporter Gene Assay Kit (Beyotime, RG005) to detect the promoter activities using a spectrophotometer (Tecan, M&#x000e4;nnedorf, Switzerland). The primers of Snail are following:</p><p id="Par57">Snail forward primer: 5&#x02032;- CTCGACCACTATGCCGCGCTC-3&#x02032;.</p><p id="Par58">Snail reverse primer: 5&#x02032;- CAAAGAGCAGCTCCAGGCAC-3&#x02032;.</p></sec><sec id="Sec18"><title>qPCR of MS2-GFP expression system</title><p id="Par59">The Measurements of RNA-MS2-GFP were performed as described previously [<xref ref-type="bibr" rid="CR29">29</xref>]. In briefly, NSCLC cells with both MS2-GFP and transcript target plasmids were grown for 36&#x02009;h at 37&#x02009;&#x000b0;C in RPMI-1640 medium supplemented with 10% FBS (Hyclone, USA), penicillin/streptomycin (100&#x02009;mg/mL). On the following day, cells were diluted in fresh medium plus antibiotics. To induce the production of MS2-GFP, 100&#x02009;ng/ml anhydrotetracycline (Cat.no: 2&#x02013;0401-001, IBA, Germany) was added to the diluted cellular culture. The expression of the target RNA was induced by the addition of IPTG and L-arabinose to the cultures. Cells were subsequently incubated with these inducers at 37&#x02009;&#x000b0;C for 1&#x02009;h with shaking to a final optical density (600&#x02009;nm) of about 0.4. Then cell lysate immunoblotted by GFP antibody were detected by qPCR with the indicated primers.</p></sec><sec id="Sec19"><title>CHIP assay</title><p id="Par60">ChIP experiments were performed according to the laboratory manual. Immunoprecipitation was performed for 6&#x02009;h or overnight at 4&#x02009;&#x000b0;C with specific antibodies. After immunoprecipitation, 45&#x02009;&#x003bc;L protein A-Sepharose and 2&#x02009;&#x003bc;g of salmon sperm DNA were added and the incubation was continued for another 1&#x02009;h. Precipitates were washed sequentially for 10&#x02009;min each in TSE I (0.1% SDS, 1% Triton X-100, 2&#x02009;mM EDTA, 20&#x02009;mM Tris-HCl, pH&#x02009;8.1, 150&#x02009;mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2&#x02009;mM EDTA, 20&#x02009;mM Tris-HCl, pH&#x02009;8.1, 500&#x02009;mM NaCl), and buffer III (0.25&#x02009;M LiCl, 1% NP-40, 1% deoxycholate, 1&#x02009;mM EDTA, 10&#x02009;mM Tris-HCl, pH&#x02009;8.1). Precipitates were then washed three times with TE buffer and extracted three times with 1% SDS, 0.1&#x02009;M NaHCO<sub>3</sub>. Eluates were pooled and heated at 65&#x02009;&#x000b0;C for at least 6&#x02009;h to reverse the formaldehyde cross-linking. DNA fragments were purified with a QIAquick Spin Kit (Qiagen, CA). For PCR, 2&#x02009;&#x003bc;L from a 5&#x02009;mL extraction and 21&#x02013;25&#x02009;cycles of amplification were used. The sequences of the primers used are provided as follows:</p><p id="Par61">Snail forward primer: 5&#x02032;-GCCCTGGCTGCTACAAGGCCATG-3&#x02032;.</p><p id="Par62">Snail reverse primer: 5&#x02032;-CTTAGCTGATGAAGAAAGTTTCTG-3&#x02032;.</p></sec><sec id="Sec20"><title>Drug treatment</title><p id="Par63">HBEC and NSCLC cells were transfected with relevant plasmids and cultured for 36&#x02009;h then treated with 10&#x02009;mM metformin (D150959, Sigma, Saint Louis, USA) followed by analysis at indicated times. For Actinomycin D (129,935, Millipore, Massachusetts, USA) treatment, A549 cells were transfected with relevant plasmids and cultured for 36&#x02009;h then treated with 5&#x02009;&#x003bc;g/mL Actinomycin D followed by analysis at indicated times.</p></sec><sec id="Sec21"><title>Human lung cancer specimen collection</title><p id="Par64">All the human lung cancer and normal lung specimens were collected in Affiliated Hospital of Binzhou Medical College with written consents of patients and the approval from the Institute Research Ethics Committee.</p></sec><sec id="Sec22"><title>In vivo experiments</title><p id="Par65">To assess the in vivo effects of miR-381 and YAP, 3 to 5-week old female BALB/c athymic (NU/NU) nude mice were housed in a level 2 biosafety laboratory and raised according to the institutional animal guidelines of Binzhou Medical University. All animal experiments were carried out with the prior approval of the Binzhou Medical University Committee on Animal Care. For the experiments, mice were injected with 5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> lung cancer cells with stably expression of relevant plasmids (five mice per group) after the diameter of the xenografted tumors had reached approximately 5&#x02009;mm in diameter. Xenografted mice were then administrated with Vehicle or Metformin (orally, 50&#x02009;mg/kg per day) for three times a week and tumor volume were measured every second day. Tumor volume was estimated as 0.5&#x02009;&#x000d7;&#x02009;a<sup>2</sup>&#x02009;&#x000d7;&#x02009;b (where a and b represent a tumors short and long diameter, respectively). Mice were euthanized after 6&#x000a0;weeks and the tumors were measured a final time. Tumor and organ tissues were then collected from xenograft mice and analyzed by immunohistochemistry.</p></sec><sec id="Sec23"><title>Immunohistochemical analysis</title><p id="Par66">All specimens were formalin-fixed and paraffin-embedded. Hematoxylin and eosin (H&#x00026;E) and immunohistochemistry (IHC) staining were performed as described previously [<xref ref-type="bibr" rid="CR30">30</xref>]. In briefly, tumor tissues were fixed in 4% paraformaldehyde overnight and then embedded in paraffin wax. Four-micrometer thick sections were and stained using hematoxylin and eosin (H&#x00026;E) for histological analysis. For IHC assay, the paraffin-embedded tissues were&#x000a0;de-waxed and then antigen-repaired for 30&#x02009;min. The activity of endogenous peroxidase was blocked by 0.3% H<sub>2</sub>O<sub>2</sub> solution. The blocking solution containing 10% FBS (Gicbo, Life Technologies, Carlsbad, CA) was used to block the non-specific antigen at room temperature for 30&#x02009;min. Then the primary antibodies of YAP and Snail were added to incubate the slide at 4&#x02009;&#x000b0;C. PBS was used as a negative control instead of the primary antibody. Finally, DAB (Kanglang Biotechnology Co., Ltd., Shanghai, China) was used to develop the color. The scoring criteria for immunohistochemistry were developed by two pathologists in our hospital.</p></sec><sec id="Sec24"><title>Statistical analysis</title><p id="Par67">Each experiment was repeated at least three times. The statistical analyses of the experiment data were performed by using a two-tailed Student&#x02019;s unpaired T-test and one-way ANOVA. Statistical significance was assessed at least three independent experiments and significance was considered at either <italic>P</italic>-value &#x0003c;&#x02009;0.05 was considered statistically significant and highlighted an asterisk in the figures, while <italic>P</italic>-values &#x0003c;&#x02009;0.01 were highlighted using two asterisks and <italic>P</italic>-values &#x0003c;&#x02009;0.001 highlighted using three asterisks in the figures.</p></sec></sec><sec id="Sec25"><title>Results</title><sec id="Sec26"><title>Decreased miR-381 promotes cellular growth, EMT, and invasion in NSCLC</title><p id="Par68">As shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, we analyzed patient demographics, tumor characteristics, and association of miR-381 levels with clinicopathological features in lung tumor samples from patients who underwent lung resection between January 2017 and January 2019. In addition, the miR-381 level was lower in NSCLC cells (A549, H1299, Calu6, H520, and 95-D) compared with normal (control) human bronchial epithelial cells (HBEC) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a). Additionally, fluorescence in situ hybridization (FISH) results indicated that miR-381 was predominantly located in the cytoplasm, where the miR-381&#x02032;s function would occur (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b). In order to explore the mechanism through which miR-381 regulates cellular growth, migration, and EMT, A549 cells were transfected with 50&#x02009;nM miR-381 mimics or inhibitors (GenePharma, Shanghai, China) for 36&#x02009;h, respectively. The level of miR-381 was increased or decreased in A549 cells upon transfection with miR-381 mimics or inhibitors, respectively (Fig. <xref rid="Fig1" ref-type="fig">1</xref>c, d). Cellular growth was promoted by downregulation of miR-381 but prevented by its upregulation in A549 cells (Fig. <xref rid="Fig1" ref-type="fig">1</xref>e, f). Contrary results were obtained for cleaved caspase 3 in A549 cells subjected to the same treatment (Fig. <xref rid="Fig1" ref-type="fig">1</xref>g, h). However, we observed similar results for clone formation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>i, j) and cell migration (Fig. <xref rid="Fig1" ref-type="fig">1</xref>k, l) in comparison with the cellular growth in the same treated A549 cells. Additionally, the EMT marker protein E-cadherin was increased or decreased in A549 cells after transfection with miR-381 mimics or inhibitors, respectively (Fig. <xref rid="Fig1" ref-type="fig">1</xref>m-o). Contrasting results for another EMT marker protein, Vimentin, were obtained in A549 cells subjected to the same treatment (Fig. <xref rid="Fig1" ref-type="fig">1</xref>&#x02009;m-o). Furthermore, endogenous miR-381 levels were lower in lung cancer tissues than in the normal adjacent tissues (<italic>n</italic>&#x02009;=&#x02009;8 in Fig. <xref rid="Fig1" ref-type="fig">1</xref><italic>n</italic> and <italic>n</italic> = 15 in Fig. <xref rid="Fig1" ref-type="fig">1</xref>o) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>p, q). We also screened publicly available datasets [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] and used to these determine the prognostic correlation between the miR-381 level and survival of patients with lung cancer. Kaplan-Meier analyses indicated that higher miR-381 levels correlated with longer overall survival (OS) (<italic>P</italic>&#x02009;=&#x02009;0.012) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>r).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient&#x02019;s demographics and tumor characteristics and association of miR-381 levels with clinicopathological features in lung tumor population</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>No. of patients, <italic>N</italic>&#x02009;=&#x02009;60 (%)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="3">Patients Parameter</td></tr><tr><td colspan="2">&#x02003;Age (years)</td><td>0.542</td></tr><tr><td>&#x02003;Average [range]</td><td>53 [25&#x02013;81]</td><td/></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;55</td><td>21 (35.0)</td><td/></tr><tr><td>&#x02003;&#x02009;&#x02265;&#x02009;55</td><td>39 (65.0)</td><td/></tr><tr><td colspan="2">Gender</td><td>0.881</td></tr><tr><td>&#x02003;Male</td><td>33 (55.0)</td><td/></tr><tr><td>&#x02003;Female</td><td>27 (45.0)</td><td/></tr><tr><td colspan="3">Tumor Characteristics</td></tr><tr><td colspan="2">&#x02003;Tumor size (cm)</td><td>0.004**</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;4</td><td>9 (15.0)</td><td/></tr><tr><td>&#x02003;&#x02009;&#x02265;&#x02009;4</td><td>51 (85.0)</td><td/></tr><tr><td colspan="2">Differentiation</td><td>0.062</td></tr><tr><td>&#x02003;Poor</td><td>39 (65.0)</td><td/></tr><tr><td>&#x02003;Well-moderate</td><td>21 (35.0)</td><td/></tr><tr><td colspan="2">Lymph node metastasis</td><td>0.034*</td></tr><tr><td>&#x02003;N-</td><td>10 (16.7)</td><td/></tr><tr><td>&#x02003;N+</td><td>50 (83.3)</td><td/></tr><tr><td colspan="2">Distant metastasis</td><td>0.039*</td></tr><tr><td>&#x02003;M-</td><td>15 (25.0)</td><td/></tr><tr><td>&#x02003;M+</td><td>45 (75.0)</td><td/></tr><tr><td colspan="3">miR-381 level</td></tr><tr><td>&#x02003;high</td><td>5 (8.3)</td><td>0.821</td></tr><tr><td>&#x02003;median</td><td>6 (10.0)</td><td>0.093</td></tr><tr><td>&#x02003;low</td><td>49 (81.7)</td><td>0.002**</td></tr></tbody></table><table-wrap-foot><p>Differences between experimental groups were assessed by Student&#x02019;s t-test or one-way analysis of variance. Data represent mean&#x02009;&#x000b1;&#x02009;SD. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>miR-381 level was lower in cancer tissues of NSCLC patients and lower miR-381 promotes cellular growth, EMT and invasion. <bold>a</bold> The miR-381 level was lower in lung cancer cells than their control cell, HBEC, by the RT-PCR and qRT-PCR assays. <bold>b</bold> FISH assay indicated that miR-381 was mainly located in the cytoplasm. <bold>c</bold>-<bold>o</bold> A549 cells were transfected with 50&#x02009;nM miR-381 mimics or miR-381 inhibitors (GenePharma, Shanghai, China), respectively. The miR-381 level was analyzed by RT-PCR and qRT-PCR assays (<bold>c</bold>, <bold>d</bold>). The cellular growth and cell viability were analyzed by CCK8 assay (<bold>e</bold>, <bold>f</bold>). The protein level of Caspase 3 Cleaved (Caspase 3-Cl) was analyzed by immunoblotting (<bold>g</bold>, <bold>h</bold>). Colony formation ability was analyzed by colony formation assay (<bold>i</bold>, <bold>j</bold>). Cellular migration growth was analyzed by scratch assay (<bold>k</bold>, <bold>l</bold>). The expressions of E-cadherin and Vimentin were analyzed by RT-PCR (<bold>m</bold>), qRT-PCR (<bold>n</bold>) and immunofluorescent staining (<bold>n</bold>) assays. <bold>p</bold>, <bold>q</bold> The miR-381 level was analyzed by RT-PCR and qRT-PCR assays in human lung cancer tissues and their normal adjacent lung tissues (<bold>p</bold>, <italic>n</italic>&#x02009;=&#x02009;8; <bold>q</bold>, <italic>n</italic>&#x02009;=&#x02009;16). (<bold>r</bold>) Kaplan Meier overall survival (OS) curves of miR-381 (<italic>p</italic>&#x02009;=&#x02009;0.012 by log-rank test for significance) for human lung cancers. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 or <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec27"><title>Increased YAP expression promotes cellular growth, invasion, and EMT in NSCLC</title><p id="Par69">Our previous study and other research indicated that YAP, as the most downstream key component of the Ste20-like kinase Hpo (MST)-YAP pathway, plays important roles in tumorigenesis and human cancer development. In addition, RT-PCR, western blotting, and qPCR results showed that the expression of YAP was higher in cell lines (A549, H1299, Calu6, H520 and 95-D) than in control cells (HBEC) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a). Additionally, YAP was highly translocated into the nucleus in the high-metastatic sub-cell line 95-D compared with the control cell line HBEC (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). In contrast, p-YAP (non-activated form of YAP), which is mainly localized to the cytoplasm, was lower in 95-D cells than in HBEC cells (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). Additionally, the expression of YAP and its target genes cellular communication network factor 1(Cyr61) and cellular communication network factor 2 (CTGF) were higher in the nucleus of 95-D cells than in that of HBEC (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). Next, in order to explore the function of YAP in the occurrence and development of human lung cancer, YAP was knocked down or overexpressed in A549 cells using siRNA (siYAP-1 and siYAP-2) or transfection with pcDNA Myc-YAP, respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref>d). We found that knockdown of YAP using siYAP-2 was more efficient (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1a) and, therefore, siYAP-2 (herein referred to as siYAP) was used to carry out the next experiments in which knockdown of YAP was required. In turn, an efficient knockdown of Snail was achieved with siSnail-1 or siSnail-2 and si-Snail-1 was further used for this purpose (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1b). Cellular growth was increased or decreased in A549 cells transfected with Myc-YAP or siYAP, respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref>e). Similar results for Ki67 (a marker for cell growth) expression (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1c), clone formation (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1d), migration (Fig. <xref rid="Fig2" ref-type="fig">2</xref>f), and invasion (Fig. <xref rid="Fig2" ref-type="fig">2</xref>g) were obtained in A549 cells under the same treatments. However, contrary results for Annexin V (a marker for apoptosis) were obtained in A549 cells in the same conditions (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1e). Moreover, the expression of E-cadherin was increased or decreased in A549 cells upon transfection with siYAP or Myc-YAP, respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref>h and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1f, g). Contrasting results regarding the expression of Vimentin were obtained in A549 cells under this treatment (Fig. <xref rid="Fig2" ref-type="fig">2</xref>&#x02009;h and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1f, g). Furthermore, RT-PCR, western blot, and qPCR results showed that the expression of YAP was higher in lung tumor tissues (<italic>n</italic>&#x02009;=&#x02009;8) than in the normal adjacent lung tissues (Fig. <xref rid="Fig2" ref-type="fig">2</xref>i, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1&#x02009;h). In addition, immunohistochemistry (IHC) results showed that YAP levels were higher and YAP was highly localized to the nuclei of cells in lung tumor tissues compared with those of cells in the normal adjacent lung tissues (Fig. <xref rid="Fig2" ref-type="fig">2</xref>j, k). Kaplan-Meier analyses of publicly available datasets [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] indicated that higher YAP levels correlated with shorter OS (<italic>P</italic>&#x02009;=&#x02009;0.023) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>l).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Higher expression of YAP promotes cellular growth, migration, invasion and EMT. <bold>a</bold> The expression of YAP was higher in NSCLC cell lines compared with their control cell line, HBEC, analyzed by RT-PCR, western blot and qRT-PCR assays. <bold>b</bold> The protein level of nuclear YAP was higher in high metastasis lung cancer cell line 95-D than its control cell HBEC by the immunofluorescent staining assay. <bold>c</bold> Immunoblotting with densitometric quantitation demonstrating increased nuclear Yap and decreased p-YAP in 95-D cells than its normal cell line meanwhile YAP&#x02019;s target genes, CTGF and Cyr61, were higher in 95-D cells. <bold>d</bold>-<bold>h</bold> A549 cells were transfected with siYAP or Myc-YAP, respectively. <bold>d</bold> The expression of YAP was analyzed by RT-PCR, Western blot and qPCR assays. <bold>e</bold> The cellular viability was analyzed by CCK8 assay. <bold>f</bold> Cellular migration growth was analyzed by scratch assay. <bold>g</bold> The cellular invasion growth was analyzed by transwell assay. <bold>h</bold> The expressions of E-cadherin and Vimentin were analyzed by RT-PCR, western blot assays. <bold>i</bold> The expression of YAP was higher in human lung cancer tissues compared with their normal adjacent lung tissues analyzed by RT-PCR, western blot and qRT-PCR assays (<italic>n</italic>&#x02009;=&#x02009;8). <bold>j</bold> Immunohistochemical (IHC) assay of the expression of YAP and Snail in the human lung cancer tissues and their normal adjacent lung tissues (<italic>n</italic>&#x02009;=&#x02009;15). <bold>k</bold> YAP was higher in nucleus from lung tumor tissues than their normal adjacent lung tissues (<italic>n</italic>&#x02009;=&#x02009;15). <bold>l</bold> Kaplan Meier overall survival (OS) curves of YAP (<italic>p</italic>&#x02009;=&#x02009;0.023 by log-rank test for significance) for human lung cancers. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 or <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec28"><title>miR-381 targets the 3&#x02019;UTR and subsequently decreases YAP mRNA stabilization</title><p id="Par70">Since miR-381 and YAP regulate cell growth, apoptosis, migration, invasion, and EMT, separately (Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>), we explored the specific function of miR-381 and YAP in lung cancer growth and metastasis. As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>a, miR-381 can target the 3&#x02019;UTR of YAP mRNA. Thus, we introduced mutations to miR-381 (miR-381 Mut) and YAP 3&#x02019;UTR (YAP 3&#x02019;UTR Mut) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a). The luciferase activity assay revealed that co-treatment of YAP-3&#x02032;UTR wild-type (WT) and overexpressed-miR-381 with mimics in A549 cells resulted in significantly lower luciferase activity compared with co-treatment with scrambled miRNA. This reduction was rescued in cells transfected with YAP-3&#x02032;UTR MUT or miR-381 inhibitors (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b). Additionally, we generated MS2 constructs containing YAP-3&#x02032;UTR WT or Mut transcripts to further detect the binding activity between miR-381 and YAP YAP-3&#x02032;UTR in HBEC and 95-D cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c). An anti-GFP RNA immunoprecipitation (RIP) assay was performed, and results showed that miR-381 was enriched in YAP-3&#x02032;UTR WT, whereas miR-381 enrichment caused by YAP-3&#x02032;UTR Mut was not significant when compared to that of the MS2 control (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c). AGO2 is essential in miRNA-induced post-transcriptional repression or degradation of RNA to form an RNA-induced silencing complex together with miRNA targets [<xref ref-type="bibr" rid="CR31">31</xref>]. This was confirmed with an anti-AGO2 RIP assay. YAP-3&#x02032;UTR enrichment was decreased or increased after knockdown or overexpression of miR-381, respectively, which was not altered by transfection with miR-381 Mut (Fig. <xref rid="Fig3" ref-type="fig">3</xref>d). To further verify the relationship between miR-381 and YAP-3&#x02032;UTR, we performed an RNA pull-down assay, which revealed that YAP-3&#x02032;UTR could be pulled down by biotin-labeled miR-381 WT. In turn, miR-381 WT could be pulled down by biotin-labeled YAP-3&#x02032;UTR WT, but miR-381 Mut or YAP-3&#x02032;UTR Mut failed to be pulled down by the biotin-labeled YAP-3&#x02032;UTR WT or biotin-labeled miR-381 WT, respectively (Fig. <xref rid="Fig3" ref-type="fig">3</xref>e-g and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2a, b). Further, FISH results indicated co-localization of miR-381 and YAP-3&#x02032;UTR in the cell cytoplasm (Fig. <xref rid="Fig3" ref-type="fig">3</xref>h). To determine whether miR-381 endogenously regulates YAP, YAP mRNA and protein levels in A549 cells were determined 36&#x02009;h after transfection with miR-381 mimics or inhibitors. Results showed that YAP mRNA and protein levels were significantly reduced in A549 cells after miR-381 mimic overexpression. These inhibitory effects were suppressed when miR-381 expression was downregulated (Fig. <xref rid="Fig3" ref-type="fig">3</xref>i-k). Furthermore, miR-381 mimics reduced but miR-381 inhibitors increased the YAP mRNA and protein levels in a dose- and time-dependent manner in A549 and 95-D cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>l-o).
<fig id="Fig3"><label>Fig. 3</label><caption><p>miR-381 targets the 3&#x02019;UTR and then decreases the mRNA stabilization of YAP. <bold>a</bold> Putative miR-381 binding sites in the 3&#x02032;-UTR sequences of YAP. <bold>b</bold> Luciferase activity of A549 cells transfected with plasmids carrying a wild-type or mutant 3&#x02032;UTR of YAP in response to miR-381 mimics or inhibitors. <bold>c</bold> Schematic images of a construction carrying a wild-type or mutant 3&#x02032;UTR of YAP combined with MS2 binding sequence (up panel). MS2-RIP followed by miR-381 qPCR to measure miR-381 associated with 3&#x02032;UTR of YAP in HBEC and 95-D cells (down panels). <bold>d</bold> AGO2-RIP followed by qPCR to evaluate 3&#x02032;UTR of YAP level after miR-381 knockdown or overexpression and miR-381 WT or Mut, respectively. <bold>e</bold> The cell lysates from A549 cells with transfection with miR-381 mimics or inhibitors were incubated with biotin-labeled miR-381 probe. The RNA level of miR-381 was analyzed by qPCR to detect the effect of probe. <bold>f</bold> A549 cells were co-transfected YAP 3&#x02032;UTR WT or Mut and then the cell lysates were incubated with biotin-labeled miR-381 WT or Mut, respectively. The relative enrichment of YAP 3&#x02032;UTR was analyzed by qPCR. <bold>g</bold> A549 cells were co-transfected miR-381 WT or Mut and then the cell lysates were incubated with biotin-labeled YAP 3&#x02032;UTR WT or Mut probe, respectively. The relative enrichment of miR-381 was analyzed by qPCR. <bold>h</bold> A549 cells were co-transfected with miR-381 and YAP 3&#x02032;UTR WT for 24&#x02009;h. The locations of YAP 3&#x02032;UTR and miR-381 were analyzed by FISH (fluorescence in situ hybridization). (<bold>i, j</bold>) A549 cells were transfected with miR-381 mimics (<bold>i</bold>) or inhibitors (<bold>j</bold>), respectively. The mRNA and protein levels of YAP were analyzed by RT-PCR, western blot and qPCR assays. <bold>k</bold> A549 cells were transfected with miR-381 mimics or inhibitors, respectively. The protein level of YAP was analyzed by immunofluorescent staining. <bold>l</bold>, <bold>m</bold> RT-PCR, western blot and qPCR results indicated that miR-381 dose- and time- dependently decreased YAP expression. <bold>n</bold>, <bold>o</bold> qPCR results indicated that miR-381 inhibitor dose- and time- dependently increased YAP, Cyr61 and CTGF expressions in A549 and 95-D cells. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 or <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance). ns, not significant</p></caption><graphic xlink:href="13046_2019_1503_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec29"><title>Metformin decreases cell growth, migration, invasion, and EMT by regulating miR-381/YAP activity</title><p id="Par71">Recent studies indicate that metformin decreases cell growth and metastasis by regulating miRNAs in human cancers [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Additionally, our previous research showed that the antineoplastic drug metformin downregulates YAP in NSCLC by interfering with IRF-1 binding to the YAP promoter [<xref ref-type="bibr" rid="CR4">4</xref>]. However, the molecular mechanism through which metformin decreases YAP activity by regulating miR-381 was not clear. Our data indicated that metformin barely affects the lung normal control cell, HBEC, but significantly decreased the NSCLC cell sublines, A549 and 95-D (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a). Incubation with metformin reduced the viability of A549 cells in a dose- and time-dependent manner, with an IC<sub>50</sub> of 19.58&#x02009;mM, 10.5&#x02009;mM, and 7.2&#x02009;mM for 24&#x02009;h, 48&#x02009;h, and 72&#x02009;h, respectively (Fig. <xref rid="Fig4" ref-type="fig">4</xref>b, c). Therefore, for subsequent experiments with metformin treatment, we treated A549 cells with 10&#x02009;mM metformin for 48&#x02009;h. FISH assay indicated that metformin increased the level of miR-381 (Fig. <xref rid="Fig4" ref-type="fig">4</xref>d). RT-PCR and qPCR results showed that metformin increased miR-381 levels in a dose- and time-dependent manner in A549 cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref>e, f). Since the decrease in RNA abundance at steady state could result from altered RNA stability, RNA decay analyses were performed. To allow for an accurate and rapid investigation of metformin involved in miR-381 stabilization, RNA degradation was analyzed by qPCR in Actinomycin D-treated NSCLC cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref>g). Confirming a role in stabilizing miR-381, cotreatment with Actinomycin D and metformin led to an increase in the stability of miR-381 compared to cotreatment with Actinomycin D and vehicle in A549, H1299 and 95-D cells. Additionally, metformin increased the stability of miR-381 in a dose-dependent manner in Actinomycin D-treated A549 and 95-D cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref>h). Moreover, metformin decreased the expression of YAP, CTGF, and Cyr61 also in a dose- and time-dependent manner (Fig. <xref rid="Fig4" ref-type="fig">4</xref>i-l and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2c). Furthermore, we explored whether metformin decreased YAP activity by regulating miR-381. The expression of YAP, CTGF, and Cyr61 was decreased in A549 cells by treatment with metformin alone, but this decrease was rescued by co-treatment with metformin and miR-381 inhibitors (Fig. <xref rid="Fig4" ref-type="fig">4</xref>m, n and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2d). Conversely, the expression of YAP, CTGF, and Cyr61 was decreased in A549 cells upon treatment with metformin alone, but this effect was aggravated by co-treatment with metformin and miR-381 mimics (Fig. <xref rid="Fig4" ref-type="fig">4</xref>o, p and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2e).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Metformin decreased YAP activity by regulating miR-381. <bold>a</bold> HBEC, A549 and 95-D cells were treated with 10&#x02009;mM metformin for indicated times. Cell viability was assessed by CCK8 assay. <bold>b</bold>, <bold>c</bold> A549 cells were incubated with metformin at various concentrations for 24, 48, and 72&#x02009;h (<bold>b</bold>) and indicated times at 5&#x02009;mM, 10&#x02009;mM and 20&#x02009;mM, respectively. Cell viability was assessed by CCK8 assay. <bold>d</bold> FISH result indicated that Metformin upregulated the RNA level of MiR-381 in the A549 cells. <bold>e</bold>, <bold>f</bold> RT-PCR and qPCR results indicated that Metformin dose- and time- dependently increased the RNA level of miR-381. <bold>g</bold> Decay of miR-381 was monitored in A549, H1299 and 95-D cells cotreated with Actinomycin D and Vehicle or 10&#x02009;mM Metformin. RNA levels of miR-381 were determined by qPCR. <bold>h</bold> Decay of miR-381 was monitored in A549 and 95-D cells cotreated with Actinomycin D and indicated concentrations of Metformin. RNA levels of miR-381 were determined by qPCR. <bold>i-k</bold> RT-PCR, qPCR (<bold>i</bold>), western blot (<bold>j</bold>) and immunofluorescent staining (<bold>k</bold>) assays indicated that Metformin dose-dependently decreased the expression of YAP. <bold>l</bold> Metformin time-dependently decreased the expression of YAP by the qPCR and western blot assays. <bold>m</bold>, <bold>n</bold> A549 cells were treated with Metformin or co-treated with Metformin and miR-381 inhibitors, respectively. The expressions of YAP, CTGF and Cyr61 were analyzed by western blot (<bold>m</bold>) and qPCR (<bold>n</bold>) assays. <bold>o</bold>, <bold>p</bold> A549 cells were treated with Metformin or co-treated with Metformin and miR-381 mimics, respectively. The expressions of YAP, CTGF and Cyr61 were analyzed by western blot (<bold>o</bold>) and qPCR (<bold>p</bold>) assays. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 or *<italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.001 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig4_HTML" id="MO4"/></fig></p><p id="Par72">In order to further understand whether metformin decreased cell growth, migration, invasion, and EMT by regulating miR-381/YAP activity, A549 cells were treated with metformin alone or in combination with miR-381 inhibitors or YAP. The expression of miR-381 and YAP was detected by qPCR (Fig. <xref rid="Fig5" ref-type="fig">5</xref>a). Additionally, cell growth was decreased in A549 cells by metformin treatment, but the inhibitory effect was prevented by co-treatment with miR-381 inhibitors or YAP (Fig. <xref rid="Fig5" ref-type="fig">5</xref>b). Similar cell viability (Fig. <xref rid="Fig5" ref-type="fig">5</xref>c), Ki67 expression (Fig. <xref rid="Fig5" ref-type="fig">5</xref>d), clone formation (Fig. <xref rid="Fig5" ref-type="fig">5</xref>e), migration (Fig. <xref rid="Fig5" ref-type="fig">5</xref>f), and invasion (Fig. <xref rid="Fig5" ref-type="fig">5</xref>g) results were obtained in A549 cells undergoing the same treatment. However, contrary results for cleaved caspase 3 were obtained in A549 cells under the same conditions (Fig. <xref rid="Fig5" ref-type="fig">5</xref>h). Moreover, the expression of E-cadherin was increased in A549 cells with separate treatment of metformin. Besides, this increase was impaired by co-treatment with metformin and miR-381 inhibitors or YAP (Fig. <xref rid="Fig5" ref-type="fig">5</xref>i, j and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2f). Contrary results for vimentin expression were obtained, under the same treatment, in A549 cells (Fig. <xref rid="Fig5" ref-type="fig">5</xref>i, j and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2f).
<fig id="Fig5"><label>Fig. 5</label><caption><p>Metformin decreased cell growth, migration, invasion and EMT by regulating miR-381/YAP activity. A549 cells were treated with Metformin or co-treated with Metformin and miR-381 inhibitors or YAP, respectively. <bold>a</bold> The RNA levels of miR-381 and YAP were analyzed by qPCR. <bold>b</bold>, <bold>c</bold> The cellular growth (<bold>b</bold>) and viability (<bold>c</bold>) were analyzed by CCK8 assay. <bold>d</bold> Ki67 positive cells were analyzed by the immunofluorescent staining assay. <bold>e</bold> Colony formation ability was analyzed by colony formation assay. <bold>f</bold> Cellular migration growth was analyzed by scratch assay. <bold>g</bold> The cellular invasion growth was analyzed by transwell assay. <bold>h</bold> The protein level of Caspase 3 Cleaved (Caspase 3-Cl) was analyzed by immunoblotting. <bold>i</bold>, <bold>j</bold> The expressions of E-cadherin and Vimentin were analyzed by RT-PCR, western blot, qPCR (<bold>i</bold>) and immunofluorescent staining (<bold>j</bold>) assays. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 or <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec30"><title>The YAP/TEAD complex directly binds to the promoter of snail, resulting in snail upregulation</title><p id="Par73">Previous studies reported that Snail, a component of an EMT-related network, increased cellular growth, migration, invasion, and EMT [<xref ref-type="bibr" rid="CR32">32</xref>]. We obtained similar results in A549 cells (Fig. <xref rid="Fig6" ref-type="fig">6</xref>a and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2&#x02009;g). Moreover, as shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>, YAP also increased cellular migration, invasion, and EMT in these cells. Next, we investigated whether regulation of Snail was involved in the effects of YAP on these biological processes. JASPAR (<ext-link ext-link-type="uri" xlink:href="http://jaspar.genereg.net">http://jaspar.genereg.net</ext-link>) analysis of the TEAD1-occupied sites identified a consensus motif (Fig. <xref rid="Fig6" ref-type="fig">6</xref>b) and we found only one TEAD1 binding site located around &#x02212;&#x02009;558 ~ &#x02212;&#x02009;553 nucleotides with respect to the transcription start site (TSS) at the <italic>Snail</italic> promoter. To further confirm the interaction between YAP/TEAD1 and Snail, we identified <italic>Snail</italic> promoter&#x02019;s core regions responsive to YAP/TEAD1. Various lengths of the <italic>Snail</italic> 5&#x02032;-flanking region, including &#x02212;&#x02009;1200/+&#x02009;100 (pGL3&#x02013;1300), &#x02212;&#x02009;1200/&#x02212;&#x02009;950 (pGL3&#x02013;250), &#x02212;&#x02009;950/&#x02212;&#x02009;600 (pGL3&#x02013;350), &#x02212;&#x02009;600/&#x02212;&#x02009;400 (pGL3&#x02013;200), &#x02212;&#x02009;400/+&#x02009;100 (pGL3&#x02013;500) and&#x02009;&#x02212;&#x02009;600/&#x02212;&#x02009;400&#x00394; (pGL3&#x02013;200&#x00394;), were cloned and transiently transfected into A549 cells expressing YAP to determine the promoter activity. The luciferase reporter gene assay indicated that pGL3&#x02013;200 exhibited maximum luciferase activity (Fig. <xref rid="Fig6" ref-type="fig">6</xref>c), demonstrating that the region encompassing &#x02212;&#x02009;600/&#x02212;&#x02009;400 is the promoter&#x02019;s core region of Snail for interaction with the YAP/TEAD1 complex. We further performed a deletion scan analysis of the region &#x02212;&#x02009;600/&#x02212;&#x02009;400 to determine the <italic>Snail</italic> promoter&#x02019;s region regulated by the YAP/TEAD1 complex. Deletion of nucleotides &#x02212;&#x02009;558 to &#x02212;&#x02009;553 abolished YAP/TEAD1-mediated activation (Fig. <xref rid="Fig6" ref-type="fig">6</xref>d). Within this region, we identified a putative YAP/TEAD1-response element spanning positions &#x02212;&#x02009;558 to &#x02212;&#x02009;553 (CATTCC) (Fig. <xref rid="Fig6" ref-type="fig">6</xref>b). In addition, YAP was able to increase the activity of pGL3&#x02013;200 in A549 cells in a dose- and time-dependent manner (Fig. <xref rid="Fig6" ref-type="fig">6</xref>e). Co-treatment of <italic>Snail</italic> WT promotor and overexpressed-YAP in A549 and H1299 cells significantly increased luciferase activity compared to co-treatment with the control plasmid, whereas luciferase activity was reduced in A549 and H1299 cells co-treatment of <italic>Snail</italic> WT promotor and knockdown- YAP. Relatively to the control group, luciferase activity did not change in neither A549 nor H1299 cells after co-treatment with <italic>Snail</italic> Mut promotor and overexpressed- or knockdown-YAP (Fig. <xref rid="Fig6" ref-type="fig">6</xref>f). Moreover, expression of <italic>Snail</italic> was increased or decreased in A549 cells upon transfection with YAP or siYAP, respectively (Fig. <xref rid="Fig6" ref-type="fig">6</xref>g, h and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2&#x02009;h). Additionally, IHC showed that Snail expression was higher in lung cancer tissues with higher YAP expression (Fig. <xref rid="Fig6" ref-type="fig">6</xref>i). Quantitative chromatin immunoprecipitation (ChIP) assays were performed to determine whether YAP/TEAD1 directly binds to <italic>Snail</italic> promoter. ChIP results indicated that co-treatment of A549 and H1299 cells with <italic>Snail</italic> promoter and overexpressed-YAP significantly promoted YAP binding to the <italic>Snail</italic> promoter, whereas knockdown-YAP did not have the same effect. Therefore, YAP/TEAD1 complex directly targets the <italic>Snail</italic> promoter (Fig. <xref rid="Fig6" ref-type="fig">6</xref>j). Additionally, YAP upregulated the expression of Snail in a dose- and time-dependent manner (Fig. <xref rid="Fig6" ref-type="fig">6</xref>k, l and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2i, j).
<fig id="Fig6"><label>Fig. 6</label><caption><p>The YAP/TEAD complex directly binds the promoter of snail resulting in upregulating Snail expression. <bold>a</bold> A549 cells were transfection with <italic>snail</italic> or <italic>si-snail</italic>, respectively. The expressions of Snail, E-cadherin and Vimentin were analyzed by RT-PCR, western blot, qPCR assays. <bold>b</bold> Consensus binding motif of TEAD1 and the binding sites of TEAD1 on the promotors of <italic>snail</italic> was predicted using JASPAR database. <bold>c</bold>, <bold>d</bold> The activities of different fragments of <italic>snail</italic> promoter were measured by luciferase reporter gene assays in A549 cells. <bold>e</bold> The activities of pGL3&#x02013;200 (&#x02212;&#x02009;600~&#x02009;&#x02212;&#x02009;400) of <italic>snail</italic> were measured by luciferase reporter gene assays in A549 cells with transfection of the indicated concentration Myc-YAP and the times. <bold>f</bold> Luciferase activities were detected in A549 or H1299 cells with transfected of plasmids carrying a wild-type or mutant promoter of <italic>snail</italic> in response to overexpressing YAP or knockdown of YAP using the siRNA in A549 and H1299 cells. <bold>g</bold>, <bold>h</bold> A549 cells were transfected with YAP or siYAP, respectively. The mRNA and protein levels of YAP and Snail were analyzed by RT-PCR, western blot, qPCR (<bold>g</bold>) and immunofluorescent staining (<bold>h</bold>) assays. <bold>i</bold> Representative IHC staining images from human lung cancer tissues for YAP and Snail (<italic>n</italic>&#x02009;=&#x02009;10). (<bold>j</bold>) Quantitative ChIP analysis demonstrating that knockdown of YAP using the siRNA decreases but overexpressing YAP increases YAP levels within the promoter region of <italic>snail</italic> in A549 and H1299 cells. <bold>k</bold>, <bold>l</bold> RT-PCR, qPCR and western blot assays indicated that YAP increased the expression of Snail in a dose- (<bold>k</bold>) and time-dependent (<bold>l</bold>) manner in A549 cells. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 or <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance). ns, not significant</p></caption><graphic xlink:href="13046_2019_1503_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec31"><title>YAP promotes NSCLC growth and metastasis by regulating snail</title><p id="Par74">In order to determine the function of YAP in NSCLC growth and metastasis, we assessed YAP/Snail in the high-metastatic lung cancer cell sub-line 95-D and control HBEC. YAP mRNA level was higher in 95-D cells than in the control cell line (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3a). The expression of YAP and Snail were higher in HBEC transfected with YAP, but lower in 95-D cells transfected with siYAP (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3b, c). Similar results were observed in HBEC and 95-D cells under the same treatment conditions regarding cell migration (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3d) and invasion (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3e). These data indicate that higher YAP enables migration and invasion of 95-D cells. Verteporfin (VP) inhibits YAP activity by disrupting the interaction between YAP and TEAD (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3f) and represses the expression of YAP target genes (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3&#x02009;g), which leads to reduced cell growth (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3&#x02009;h), migration (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3i), and invasion (Additional&#x000a0;file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3j), while inducing apoptosis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3k) [<xref ref-type="bibr" rid="CR33">33</xref>]. Next, we explored the influence of VP on YAP function for promoting cell migration and invasion via Snail in HBEC overexpressing YAP. HBEC were either transfected to overexpress YAP or co-treated with VP and YAP. Expression of Snail and vimentin was increased but that of E-cadherin was decreased in HBEC overexpressing YAP. However, this effect was diminished by co-treatment with VP and YAP when compared with overexpression of YAP (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4a, b). Similar results for cell migration (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4c), invasion (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4d), growth and viability (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4e), and Ki67 expression (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4f) were obtained in the same treated HBEC cells. Contrary results for cleaved caspase 3 were obtained in HBEC under the same treatment (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4&#x02009;g).</p><p id="Par75">To further confirm the correlation between YAP/Snail and cell growth and metastasis in lung cancer, we quantified the expressions of YAP and Snail in lung cancer tissues. IHC results indicated that Snail was highly expressed in YAP-positive lung cancer tissues (Fig. <xref rid="Fig6" ref-type="fig">6</xref>i). Moreover, YAP and Snail expression was increased in lung cancer tissues undergoing metastasis (after-M) compared with pro-metastasis (pro-M) from the same patient (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a). Furthermore, YAP and Snail expression was increased in tissues from lung cancer metastases (TIM) compared to those from lung cancer in situ (TIS) (Fig. <xref rid="Fig7" ref-type="fig">7</xref>b). We then examined the expression of Snail in HBEC and 95-D cells. The results showed that Snail expression was higher in 95-D cells than in HBEC (Fig. <xref rid="Fig7" ref-type="fig">7</xref>c, d and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2k). Moreover, the expression of Snail was higher in HBEC transfected with Snail, but lower in 95-D cells transfected with si-Snail in comparison with the respective controls (Fig. <xref rid="Fig7" ref-type="fig">7</xref>e). We obtained similar results for cell growth (Fig. <xref rid="Fig7" ref-type="fig">7</xref>f) and migration (Fig. <xref rid="Fig7" ref-type="fig">7</xref>g) in HBEC and 95-D under the same treatment. Next, we explored whether YAP promotes cell migration, invasion, and EMT by regulating Snail. HBEC cells were transfected with YAP or co-transfected with YAP and si-Snail while 95-D cells were transfected with siYAP or co-transfected with siYAP and Snail. The expression of YAP and Snail was detected by RT-PCR, western blotting, and qPCR in the aforementioned treatment HBEC and 95-D cells (Fig. <xref rid="Fig7" ref-type="fig">7</xref>h, i and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2&#x02009;l, m). Cellular viability was increased in HBEC transfected with YAP, but this increase was rescued by co-treatment of overexpressed-YAP and knockdown-Snail (Fig. <xref rid="Fig7" ref-type="fig">7</xref>j). Cellular viability was decreased in 95-D cells transfected with siYAP, but this decrease was rescued by co-treatment of knockdown-YAP and overexpressed-Snail (Fig. <xref rid="Fig7" ref-type="fig">7</xref>k). Similar results for cellular migration (Fig. <xref rid="Fig7" ref-type="fig">7</xref>l and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S5a) and invasion (Fig. <xref rid="Fig7" ref-type="fig">7</xref>m and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S5b), and contrary results for annexin V (Fig. <xref rid="Fig7" ref-type="fig">7</xref>n) were obtained in HBEC and 95-D cells subjected to the same treatment. Furthermore, E-cadherin was decreased but vimentin was increased in HBEC transfected with YAP. However, these changes were rescued in HBEC cells with co-treatment of overexpressed-YAP and knockdown-Snail (Fig. <xref rid="Fig7" ref-type="fig">7</xref>o and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2n). Additionally, E-cadherin was increased but vimentin was decreased in 95-D cells transfected with siYAP. However, these effects were repressed by co-treatment of knockdown-YAP and overexpressed-Snail (Fig. <xref rid="Fig7" ref-type="fig">7</xref>p and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2o).
<fig id="Fig7"><label>Fig. 7</label><caption><p>YAP promotes cell migration, invasion and EMT by regulating <italic>snail.</italic>
<bold>a</bold> IHC assay of the expression of YAP and Snail in the human lung cancer tissues from pro-metastasis (Pro-M) and after-metastasis (After-M) (<italic>n</italic>&#x02009;=&#x02009;10). <bold>b</bold> IHC assay of the expression of YAP and Snail from the tumor in situ (TIS) and tumor in metastasis (TIM) of lung cancers (<italic>n</italic>&#x02009;=&#x02009;10). <bold>c</bold>, <bold>d</bold> The expression of Snail was detected in the HBEC and 95-D cells by RT-PCR, western blot, qPCR (<bold>c</bold>) and immunofluorescent staining (<bold>d</bold>) assays. e<bold>-g</bold> HBEC cells were transfected with <italic>snail</italic> or 95-D cells were transfected with <italic>si-snail</italic>, respectively. The expression of Snail was analyzed by RT-PCR, qPCR and western blot assays (<bold>e</bold>). The cellular viability was analyzed by CCK8 assay (<bold>f</bold>). The cellular migration growth was analyzed by scratch assay (<bold>g</bold>). <bold>h-p</bold> HBEC cells were transfected with YAP or co-transfected with YAP and si-snail, meanwhile 95-D cells were transfected with siYAP or co-transfected with siYAP and snail, respectively. The expressions of YAP and Snail were analyzed by RT-PCR, western blot and qPCR in HEBC and 95-D cells (<bold>h</bold>, <bold>i</bold>). The cellular viability was analyzed by CCK8 assay in HEBC (<bold>j</bold>) and 95-D cells (<bold>k</bold>). The cellular migration growth was analyzed by scratch assay in HBEC cells (<bold>l</bold>). The cell migration and invasion were analyzed by transwell assay in HBEC cells (<bold>m</bold>). The expression of Annexin V was analyzed by immunofluorescent staining assays in 95-D cells (<bold>n</bold>). The expressions of Vimentin and E-cadherin were analyzed by RT-PCR, western blot and qPCR in HEBC and 95-D cells (<bold>o</bold>, <bold>p</bold>). Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <italic>*P</italic>&#x02009;&#x0003c;&#x02009;0.05 or <italic>**P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec32"><title>Metformin inhibits lung cancer growth and metastasis by regulation of the miR-381-YAP-snail axis in vivo and in vitro</title><p id="Par76">We explored whether metformin inhibits NSCLC tumor growth and metastasis via the regulation of miR-381 in vivo. First, we established A549 cell lines stably overexpressing scrambled RNA and miR-381 inhibitors (miR-381 i). We used these cells to generate a mouse cell growth and metastasis xenograft model. When the xenografted tumors had reached approximately 5&#x02009;mm in diameter, xenografted mice were administrated the vehicle or metformin each day for 6&#x000a0;weeks. The tumor volume of the miR-381 inhibitors group was significantly smaller in the metformin-treated group compared to that in the vehicle-treated group (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a, b). Moreover, the metformin-treated miR-381 inhibitor group had longer survival times than the vehicle-treated miR-381 inhibitor group (Fig. <xref rid="Fig8" ref-type="fig">8</xref>c). The IHC assay revealed that the protein levels of Ki67, YAP, Snail, and vimentin were lower in cancer tissues from the metformin-treated miR-381 inhibitor group than in tissues from the vehicle-treated miR-381 inhibitor group (Fig. <xref rid="Fig8" ref-type="fig">8</xref>d). However, cleaved caspase 3 and E-cadherin expressions were obtained the contrary results determined by IHC assay (Fig. <xref rid="Fig8" ref-type="fig">8</xref>d). Furthermore, significantly fewer and smaller metastatic&#x000a0;lung tumors originated from the xenografted tumors in the metformin-treated miR-381 inhibitor group than in the vehicle-treated miR-381 inhibitor group (Fig. <xref rid="Fig8" ref-type="fig">8</xref>e-h).
<fig id="Fig8"><label>Fig. 8</label><caption><p>Metformin inhibits xenograft tumor growth and metastasis in vivo <italic>and</italic> in vitro<italic>.</italic>
<bold>a</bold>, <bold>b</bold> Xenografted A549 cell tumors with stably expressing Scramble miRNA and miR-381 inhibitors (miR-381 i) in mice with treatment of vehicle and metformin. The weights (<bold>a</bold>) and sizes (<bold>b</bold>) measured at regular intervals. <bold>c</bold> Kaplan-Meier overall survival (OS) curves of vehicle- and metformin-treated mice injected A549 cells with stably expressing Scramble miRNA and miR-381 inhibitors. <bold>d</bold> The expressions of Ki67, Cleaved Caspase3, YAP, Snail, E-cadherin and Vimentin were analyzed by immunohistochemistry assay from tumor tissues injected A549 cells with stably expressing Scramble miRNA and miR-381 inhibitors in mice with treatment of vehicle and metformin (<italic>n</italic>&#x02009;=&#x02009;5). <bold>e-h</bold> Representative H&#x00026;E stained microscopic images of the metastatic&#x000a0;lung tumors originated from xenografted A549 cells with stably expressing Scramble miRNA and miR-381 inhibitors in mice with treatment of vehicle and metformin by subcutaneous injection. <bold>i-o</bold> 95-D cells were separately treated with metformin or co-treated with metformin and Snail, respectively. <bold>i</bold> The expressions of YAP and Snail were analyzed by RT-PCR and qPCR. <bold>j</bold> The cellular viability was analyzed by CCK8. <bold>k</bold> The cellular migration growth was analyzed by scratch assay. <bold>l</bold> The cell migration and invasion were analyzed by transwell assay. <bold>m-o</bold> The expressions of YAP, Snail, E-cadherin and Vimentin were analyzed by RT-PCR (<bold>m</bold>), qPCR (<bold>n</bold>) and western blot (<bold>o</bold>) assays. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig8_HTML" id="MO8"/></fig></p><p id="Par77">Next, we explored the contribution of metformin to the decreased cell growth, migration, invasion, and EMT by regulation of Snail in vitro. 95-D cells were treated with metformin or co-treated with metformin and Snail. The expression of Snail was decreased in metformin-treated cells compared with vehicle-treated cells. However, this decrease was rescued by co-treatment with metformin and Snail (Fig. <xref rid="Fig8" ref-type="fig">8</xref>i). Similar results of cell viability (Fig. <xref rid="Fig8" ref-type="fig">8</xref>j), migration (Fig. <xref rid="Fig8" ref-type="fig">8</xref>k), invasion (Fig. <xref rid="Fig8" ref-type="fig">8</xref>l), and vimentin levels (Fig. <xref rid="Fig8" ref-type="fig">8</xref>m-o) were obtained, with contrary results for E-cadherin expression (Fig. <xref rid="Fig8" ref-type="fig">8</xref>&#x02009;m-o), in 95-D cells subjected to the same treatment.</p><p id="Par78">Furthermore, to confirm the correlation between miR-381, YAP, and Snail and human lung cancer metastasis in vivo, we established A549 lines stably overexpressing miR-381 inhibitors (miR-381 inh&#x02009;+&#x02009;shNC), co-overexpressing miR-381 inhibitors and shYAP (miR-381 inh&#x02009;+&#x02009;shYAP), and control cells (control+shNC). We used these cells to generate a mouse cell growth and metastasis xenograft model. First, miR-381 and YAP expression levels were analyzed using RT-PCR, western blotting, and qPCR to validate the constructed cell lines (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>a). Approximately 2&#x02009;weeks after subcutaneous implantation of control+shNC, miR-381 inh&#x02009;+&#x02009;shNC, and miR-381 inh&#x02009;+&#x02009;shYAP cells into nude mice, the tumor volume of the miR-381 inh&#x02009;+&#x02009;shNC group was significantly larger than that of the control+shNC group (Fig. <xref rid="Fig9" ref-type="fig">9</xref>b, c). Moreover, the growth of tumors was repressed in the miR-381 inh&#x02009;+&#x02009;shYAP group compared with the miR-381 inh&#x02009;+&#x02009;shNC group (Fig. <xref rid="Fig9" ref-type="fig">9</xref>b, c). miR-381 inh&#x02009;+&#x02009;shYAP mice had longer survival times than miR-381 inh&#x02009;+&#x02009;shNC mice (Fig. <xref rid="Fig9" ref-type="fig">9</xref>d). Results of IHC, RT-PCR, western blotting, and qPCR assays showed that the protein and mRNA levels of Ki67, YAP, Snail, and vimentin were lower in miR-381 inh&#x02009;+&#x02009;shYAP cancer tissues than in miR-381 inh&#x02009;+&#x02009;shNC cancer tissues (Fig. <xref rid="Fig9" ref-type="fig">9</xref>e, f). In contrast, cleaved caspase 3 and E-cadherin expression was higher in miR-381 inh&#x02009;+&#x02009;shYAP cancer tissues than in miR-381 inh&#x02009;+&#x02009;shNC cancer tissues (Fig. <xref rid="Fig9" ref-type="fig">9</xref>e, f). Furthermore, significantly fewer and smaller lung tumors originated from the xenografted tumors in the miR-381 inh&#x02009;+&#x02009;shYAP nude mice than in the miR-381 inh&#x02009;+&#x02009;shNC nude mice (Fig. <xref rid="Fig9" ref-type="fig">9</xref>g). The expression of Ki67, YAP, Snail, and vimentin were higher, but E-cadherin was lower in the metastatic lung cancer originated from the xenografted tumors (Fig. <xref rid="Fig9" ref-type="fig">9</xref>h).
<fig id="Fig9"><label>Fig. 9</label><caption><p>miR-381 inhibits lung cancer growth and metastasis in vivo by regulating snail via YAP. <bold>a</bold> RT-PCR, western blot, and qPCR analysis of the protein and mRNA levels of miR-381 and&#x000a0;YAP in the A549 cells with stable expressions of controls (control<sup>shNC</sup>), miR-381 inhibitors (miR-381 inhibitors<sup>shNC</sup>) or co- expressions of miR-381 inhibitors and shYAP (miR-381 inhibitors<sup>shYAP</sup>). <bold>b</bold>, <bold>c</bold> Xenografted A549 cell tumors with stably expressing control<sup>shNC</sup>, miR-381 inhibitors<sup>shNC</sup> and miR-381 inhibitors<sup>shYAP</sup> in mice and the weights (<bold>b</bold>) and sizes (<bold>c</bold>) measured at regular intervals. <bold>d</bold> Kaplan-Meier overall survival (OS) curves of mice injected A549 cells with stably expressing control<sup>shNC</sup>, miR-381 inhibitors<sup>shNC</sup> and miR-381 inhibitors<sup>shYAP</sup>. <bold>e</bold>, <bold>f</bold> The expressions of Ki67, Cleaved Caspase3, YAP, Snail, E-cadherin and Vimentin were analyzed by immunohistochemistry (<bold>e</bold>), RT-PCR, western blot and qPCR (<bold>f</bold>) assays from tumor tissues injected A549 cells with stably expressing control<sup>shNC</sup>, miR-381 inhibitors<sup>shNC</sup> and miR-381 inhibitors<sup>shYAP</sup> in mice (<italic>n</italic>&#x02009;=&#x02009;5). <bold>g</bold> Representative H&#x00026;E stained microscopic images of the lung tumors originated from xenografted A549 cells with stably expressing control<sup>shNC</sup>, miR-381 inhibitors<sup>shNC</sup> and miR-381 inhibitors<sup>shYAP</sup> in mice by subcutaneous injection. <bold>h</bold> The mRNA levels of miR-381, Ki67, YAP, Snail, E-cadherin and Vimentin were analyzed by were qPCR in the lung tumors originated from xenografted A549 cells with stably expressing control<sup>shNC</sup>, miR-381 inhibitors<sup>shNC</sup> and miR-381 inhibitors<sup>shYAP</sup> in mice by subcutaneous injection. Results were presented as mean&#x02009;&#x000b1;&#x02009;SD, and the error bars represent the SD of three independent experiments. <bold>i</bold> The diagram of metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.&#x000a0;**<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups (two-tailed, unpaired Student&#x02019;s t-test or one-way analysis of variance)</p></caption><graphic xlink:href="13046_2019_1503_Fig9_HTML" id="MO9"/></fig></p></sec></sec><sec id="Sec33"><title>Discussion</title><p id="Par79">Lung cancer has the highest incidence and mortality rates of all cancers, globally. With increases in environmental pollution and smoking, it has become the primary threat to people&#x02019;s health. Currently, routine clinical treatment includes surgical resection, chemotherapy, and radiotherapy. However, chemotherapeutic drugs often present poor specificity, and induce side effects and tumor resistance. Moreover, cancer metastasis is the main cause of lung cancer clinical treatment failure, leading to very low cure and five-year survival rates [<xref ref-type="bibr" rid="CR34">34</xref>]. Therefore, finding new targets for the diagnosis and treatment of lung cancer has become an urgent clinical problem.</p><p id="Par80">Our data show that miR-381 expression is downregulated in NSCLC cells and patient specimens, inhibiting cell proliferation, migration, invasion, and EMT, and promoting cell apoptosis (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), opposite to YAP expression and YAP-mediated effects (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Moreover, miR-381 (GenePharma, Shanghai, China) bound to the 3&#x02019;UTR of YAP mRNA and reduced YAP expression in a dose and time-dependent manner (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). We also found that metformin decreased YAP activity via upregulating miR-381 and inhibited cell proliferation, migration, invasion, and EMT but induced apoptosis (Figs.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref>). Furthermore, YAP bound to the promoter of <italic>Snail</italic> and regulated its expression at the transcription level, therefore mediating the metformin-induced biological processes mentioned above (Figs.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref> and <xref rid="Fig7" ref-type="fig">7</xref>). Importantly, miR-381 inhibited lung cancer growth and metastasis in vivo by regulating YAP (Fig. <xref rid="Fig9" ref-type="fig">9</xref>). These data indicated that miR-381, YAP, and Snail constitute a signal transduction pathway, known as the miR-381-YAP-Snail signal axis, which was repressed by metformin, and reduce lung cancer cell invasiveness (which is regulated by EMT in lung cells) and&#x000a0;migration (Fig. <xref rid="Fig9" ref-type="fig">9i</xref>).</p><p id="Par81">Metformin is a first-line hypoglycemic drug that has been used in the clinic for more than half a century and has proven to be efficacious in treatment of type 2 diabetes mellitus. Recently published studies have shown that it can reduce the risk of tumor development, and data from case-control studies corroborated this [<xref ref-type="bibr" rid="CR35">35</xref>]. The anti-cancer effect of metformin results from its ability to interfere with several biological processes including: inhibition of tumor cell proliferation by activation of adenosine monophosphate-activated protein kinase [<xref ref-type="bibr" rid="CR36">36</xref>]; regulation of insulin/insulin-like growth factor 1 axis activity [<xref ref-type="bibr" rid="CR37">37</xref>]; induction of tumor cell cycle arrest and apoptosis [<xref ref-type="bibr" rid="CR38">38</xref>]; and regulation of energy metabolism [<xref ref-type="bibr" rid="CR39">39</xref>]. These data indicate that metformin has a clear role in tumor prevention and, therefore, the prolonged and increased use of metformin can significantly reduce the risk of malignant tumors. Moreover, our previously published research showed that metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter, and inhibits cancer growth and metastasis in NSCLC [<xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, recent studies have shown that metformin inhibits human cancer growth and metastasis by regulating miRNAs [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. As demonstrated in this study, metformin upregulates the level of miR-381 but whether this regulatory effect occurs at the pri-, pre-miRNA, or post-transcriptional level remains unclear and needs to be further explored. Metformin treatment decreases the levels of miR-381 decay as demonstrated by our study (Fig. <xref rid="Fig4" ref-type="fig">4</xref>f, g). Therefore, these data indicated that metformin has potential as an effective drug for the treatment of human cancers, but further research is required to elucidate the underlying molecular mechanisms.</p><p id="Par82">miRNAs extensively participate in cell growth, development, differentiation, metabolism, and defense mechanisms. Moreover, it has been found that miRNA, as a small molecular product regulated by gene expression, may be used as a tumor marker for early diagnosis of tumors and to determine the prognosis and recurrence of a tumor, revealing a correlation between miRNA expression and tumor occurrence [<xref ref-type="bibr" rid="CR40">40</xref>]. In addition, recent studies have shown that miR-381 has a very important role in tumor oncogenesis, development, metastasis and chemical resistance. For example, miR-381 inhibits the proliferation and invasion of prostate cancer cells via the regulation of UBE2C [<xref ref-type="bibr" rid="CR41">41</xref>]; miR-381 inhibits lung adenocarcinoma progression by directly targeting LMO3 through the regulation of the PI3K/Akt signaling pathway and EMT [<xref ref-type="bibr" rid="CR42">42</xref>]; up-regulation of miR-381 inhibits the NAD<sup>+</sup> salvage pathway and promotes apoptosis in breast cancer cells [<xref ref-type="bibr" rid="CR43">43</xref>]; miR-381 overcomes cisplatin resistance in breast cancer cells by targeting MDR1 [<xref ref-type="bibr" rid="CR44">44</xref>]. In line with these findings, metformin upregulated the level of miR-381 to inhibit NSCLC tumor growth and metastasis in our study. Therefore, these findings provide us with a new tool for the study of tumor pathogenesis and help us to find molecular markers for early tumor diagnosis and the establishment of an effective miRNA targeted therapy, which is greatly significant to the improvement of survival rates of cancer patients.</p><p id="Par83">YAP is the main downstream effector of the Hippo pathway, which is highly conserved in mammals. The Hippo pathway can regulate the steady-state of tissues, cell proliferation, apoptosis, organ size, regeneration, and tumor formation [<xref ref-type="bibr" rid="CR17">17</xref>]. Some of the components of the Hippo pathway can inhibit cell proliferation, promote apoptosis, and regulate stem cell/progenitor cell expansion, thus playing an important role in regulating organ growth [<xref ref-type="bibr" rid="CR17">17</xref>]. Dysfunction of the core components of the Hippo pathway can cause overgrowth of an organ. For instance, if the Hippo pathway is inactivated, YAP dephosphorylation can be induced, and the expression of genes related to cell proliferation, reprogramming, stem cell activity, EMT, and anti-apoptosis can be upregulated [<xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, YAP is overexpressed in a variety of tumors, such as NSCLC, liver, gastric, colorectal, and small cell lung cancer, and therefore can be used as a marker of poor prognosis in these tumors [<xref ref-type="bibr" rid="CR46">46</xref>]. Hence, it is urgent to clarify the correlation between YAP and human tumorigenesis and development, and its importance in cancer treatment efficiency, which directly impacts cancer patients quality of life and the economic burden caused by cancer [<xref ref-type="bibr" rid="CR46">46</xref>]. However, previous research mainly focused on the identification of new components and specific intermolecular mechanisms of known core proteins in the MST-YAP pathway. Additionally, there is little research on the regulation of YAP levels, particularly at the transcriptional level. In this study, we showed that miR-381 directly targets 3&#x02032;UTR of YAP mRNA, consequently reducing the stability of YAP mRNA at the transcriptional level. Thus, our study provides a deeper insight in the relationship between YAP and human cancers.</p></sec><sec id="Sec34"><title>Conclusion</title><p id="Par84">This study demonstrated that miR-381, YAP, and Snail constitute the miR-381-YAP-Snail signal axis, which is regulated by metformin, and controls NSCLC cell invasiveness by directly regulating EMT. Our findings indicated a novel molecular mechanism underlying the tumorigenesis, progression and metastasis of NSCLC. We believe that the miR-381-YAP-Snail signal axis may be a suitable diagnostic marker and a potential therapeutic target for lung cancer.</p></sec><sec id="Sec35" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13046_2019_1503_MOESM1_ESM.docx"><caption><p><bold>Additional file 1: Figure S1</bold>. Increased YAP expression promotes cellular growth and migration. <bold>Figure S2</bold>. Metformin decreases the expressions of YAP and Snail. <bold>Figure S3</bold>. Verteporfin inhibits cellular growth and migration. <bold>Figure S4</bold>. Verteporfin disrupted the interaction between YAP and TEAD. HBEC cells were treated with YAP or co-treated with YAP and verteporfin, respectively. <bold>Figure S5</bold>. YAP promotes cell migration, invasion, and EMT by regulating Snail. 95-D cells were transfected with siYAP or co-transfected with siYAP and snail, respectively. </p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>3&#x02032;-UTR</term><def><p id="Par5">3&#x02032;-untranslated regions</p></def></def-item><def-item><term>EMT</term><def><p id="Par6">Epithelial-to-mesenchymal transition</p></def></def-item><def-item><term>HBEC</term><def><p id="Par7">Human bronchial epithelial cells</p></def></def-item><def-item><term>miR-381</term><def><p id="Par8">MicroRNA-381</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par9">Non-small cell lung cancer</p></def></def-item><def-item><term>shRNA</term><def><p id="Par10">Short hairpin RNA</p></def></def-item><def-item><term>siRNA</term><def><p id="Par11">Short interfering RNA</p></def></def-item><def-item><term>Snail</term><def><p id="Par12">Snail family transcriptional repressor 1</p></def></def-item><def-item><term>YAP</term><def><p id="Par13">Yes associated protein 1</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>This article has been retracted. Please see the retraction notice for more detail:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13046-025-03331-9">https://doi.org/10.1186/s13046-025-03331-9</ext-link></p></fn><fn><p>Dan Jin and Jiwei Guo contributed equally to this work.</p></fn><fn><p><bold>Change history</bold></p><p>12/9/2022</p><p>A Correction to this paper has been published: 10.1186/s13046-022-02545-5</p></fn><fn><p><bold>Change history</bold></p><p>2/27/2025</p><p>This article has been retracted. Please see the Retraction Notice for more detail: 10.1186/s13046-025-03331-9</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13046-019-1503-6.</p></sec><ack><p>We appreciate Professor Sichuan. Xi (National Institutes of Health, USA) for critical reading of the manuscript.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JG directed and supervised the study and revised the manuscript; DJ designed and performed most of the experiments; YW, WC, XW, JDu, LY, KG, JDai, SM, XL and GS participated in some experiments; JG and DJ analyzed the data and competed the figures; JG wrote the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by National Natural Science Foundation of China (No. 31801085, No. 81903102, No. 31900441, NO. 81902702 and No. 81903537), Natural Science Foundation of Shandong Province (ZR2018QH004 and ZR2019MC026), The Key Research and Development Program of Shandong Province (2019GSF108174 and 2019GSF107099) and Youth Talents Plan of Binzhou Medical University Hospital (JC2019&#x02013;06).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Supplementary methods and materials and Figs. S1 to S6 are attached.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par85">The experimental protocol was approved by the Research Ethics Committee of Binzhou Medical University, China (No. 2018&#x02013;018-01 for human lung cancer specimen and No. 2018&#x02013;010-10 for mouse experiments in vivo) and the written informed consent was obtained from all subjects. Informed consent was obtained from all individual participants included in the study. All patients were staged based on the criteria of the 7th Edition of the AJCC Cancer Staging Manual (2010).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par86">The authors confirm that they have obtained written consent from each patient to publish the manuscript.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par87">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Kelekar</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Mita</surname><given-names>M</given-names></name></person-group><article-title>The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development</article-title><source>Target Oncol</source><year>2016</year><volume>11</volume><fpage>447</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1007/s11523-016-0423-z</pub-id><pub-id pub-id-type="pmid">26864078</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Gong J, Kelekar G, Shen J, Shen J, Kaur S, Mita M. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Target Oncol. 2016;11:447&#x02013;67.<pub-id pub-id-type="pmid">26864078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>M</given-names></name><name><surname>Darko</surname><given-names>KO</given-names></name><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Combination of metformin with chemotherapeutic drugs via different molecular mechanisms</article-title><source>Cancer Treat Rev</source><year>2017</year><volume>54</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2017.01.005</pub-id><pub-id pub-id-type="pmid">28161619</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Peng M, Darko KO, Tao T, Huang Y, Su Q, He C, Yin T, Liu Z, Yang X. Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treat Rev. 2017;54:24&#x02013;33.<pub-id pub-id-type="pmid">28161619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>JH</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>Interplay between YAP/TAZ and metabolism</article-title><source>Cell Metab</source><year>2018</year><volume>28</volume><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.07.010</pub-id><pub-id pub-id-type="pmid">30089241</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Koo JH, Guan KL. Interplay between YAP/TAZ and metabolism. Cell Metab. 2018;28:196&#x02013;206.<pub-id pub-id-type="pmid">30089241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name></person-group><article-title>The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC</article-title><source>Ebiomedicine</source><year>2018</year><volume>37</volume><fpage>188</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.10.044</pub-id><pub-id pub-id-type="pmid">30389502</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Jin D, Guo J, Wang D, Wu Y, Wang X, Gao Y, Shao C, Xu X, Tan S. The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC. Ebiomedicine. 2018;37:188&#x02013;204.<pub-id pub-id-type="pmid">30389502</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Mallik</surname><given-names>R</given-names></name><name><surname>Chowdhury</surname><given-names>TA</given-names></name></person-group><article-title>Metformin in cancer</article-title><source>Diabetes Res Clin Pract</source><year>2018</year><volume>143</volume><fpage>409</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2018.05.023</pub-id><pub-id pub-id-type="pmid">29807101</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract. 2018;143:409&#x02013;19.<pub-id pub-id-type="pmid">29807101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Crawley</surname><given-names>D</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Cathcart</surname><given-names>P</given-names></name><name><surname>Challacombe</surname><given-names>B</given-names></name><name><surname>Cook</surname><given-names>G</given-names></name><name><surname>Cahill</surname><given-names>D</given-names></name><name><surname>Santa</surname><given-names>OA</given-names></name><name><surname>Cahill</surname><given-names>F</given-names></name><etal/></person-group><article-title>Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><fpage>494</fpage><pub-id pub-id-type="doi">10.1186/s12885-017-3458-3</pub-id><pub-id pub-id-type="pmid">28732480</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, Cook G, Cahill D, Santa OA, Cahill F, et al. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. BMC Cancer. 2017;17:494.<pub-id pub-id-type="pmid">28732480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsilidis</surname><given-names>KK</given-names></name><name><surname>Capothanassi</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>NE</given-names></name><name><surname>Rizos</surname><given-names>EC</given-names></name><name><surname>Lopez</surname><given-names>DS</given-names></name><name><surname>van Veldhoven</surname><given-names>K</given-names></name><name><surname>Sacerdote</surname><given-names>C</given-names></name><name><surname>Ashby</surname><given-names>D</given-names></name><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><article-title>Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research Datalink analyzed like an intention-to-treat trial</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>2522</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.2337/dc14-0584</pub-id><pub-id pub-id-type="pmid">24898303</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP. Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37:2522&#x02013;32.<pub-id pub-id-type="pmid">24898303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, Silini EM, Sabbioni S, Negrini M. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene. 2019.</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Tseng HW, Li SC, Tsai KW. Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression. Cancers (Basel). 2019;11.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells</article-title><source>Eur J Pharmacol</source><year>2018</year><volume>830</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.04.027</pub-id><pub-id pub-id-type="pmid">29704494</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Xia C, Liang S, He Z, Zhu X, Chen R, Chen J. Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. Eur J Pharmacol. 2018;830:59&#x02013;67.<pub-id pub-id-type="pmid">29704494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RS</given-names></name><name><surname>Zheng</surname><given-names>YL</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chun</surname><given-names>X</given-names></name></person-group><article-title>microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-kappaB signaling</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>98</volume><fpage>538</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.12.092</pub-id><pub-id pub-id-type="pmid">29287202</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Huang RS, Zheng YL, Zhao J, Chun X. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-kappaB signaling. Biomed Pharmacother. 2018;98:538&#x02013;44.<pub-id pub-id-type="pmid">29287202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name></person-group><article-title>miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>86</volume><fpage>426</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.12.051</pub-id><pub-id pub-id-type="pmid">28012397</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Xue Y, Xu W, Zhao W, Wang W, Zhang D, Wu P. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. Biomed Pharmacother. 2017;86:426&#x02013;33.<pub-id pub-id-type="pmid">28012397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bian</surname><given-names>W</given-names></name></person-group><article-title>miR381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer</article-title><source>Int J Mol Med</source><year>2019</year><volume>44</volume><fpage>593</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">31173154</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Qiao G, Li J, Wang J, Wang Z, Bian W. miR381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer. Int J Mol Med. 2019;44:593&#x02013;607.<pub-id pub-id-type="pmid">31173154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><article-title>Long non-coding RNA DLEU1 promotes proliferation and invasion by interacting with miR-381 and enhancing HOXA13 expression in cervical Cancer</article-title><source>Front Genet</source><year>2018</year><volume>9</volume><fpage>629</fpage><pub-id pub-id-type="doi">10.3389/fgene.2018.00629</pub-id><pub-id pub-id-type="pmid">30581456</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liu C, Tian X, Zhang J, Jiang L. Long non-coding RNA DLEU1 promotes proliferation and invasion by interacting with miR-381 and enhancing HOXA13 expression in cervical Cancer. Front Genet. 2018;9:629.<pub-id pub-id-type="pmid">30581456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ji</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression</article-title><source>J Exp Clin Cancer Res</source><year>2017</year><volume>36</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13046-017-0499-z</pub-id><pub-id pub-id-type="pmid">28193228</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W, Wang L. MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 2017;36:29.<pub-id pub-id-type="pmid">28193228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lou</surname><given-names>G</given-names></name></person-group><article-title>MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>9157</fpage><lpage>9167</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-4805-8</pub-id><pub-id pub-id-type="pmid">26768613</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Xia B, Li H, Yang S, Liu T, Lou G. MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol. 2016;37:9157&#x02013;67.<pub-id pub-id-type="pmid">26768613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>FX</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>Hippo pathway in organ size control, tissue homeostasis, and Cancer</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>811</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.044</pub-id><pub-id pub-id-type="pmid">26544935</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and Cancer. Cell. 2015;163:811&#x02013;28.<pub-id pub-id-type="pmid">26544935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Warren J, Xiao Y, Lamar JM. YAP/TAZ Activation as a Target for Treating Metastatic Cancer. Cancers (Basel). 2018;10.</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Cornils</surname><given-names>H</given-names></name><name><surname>Kohler</surname><given-names>RS</given-names></name><name><surname>Hergovich</surname><given-names>A</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><article-title>Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression</article-title><source>Cell Cycle</source><year>2011</year><volume>10</volume><fpage>1897</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.4161/cc.10.12.15826</pub-id><pub-id pub-id-type="pmid">21593588</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Cornils H, Kohler RS, Hergovich A, Hemmings BA. Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. Cell Cycle. 2011;10:1897&#x02013;904.<pub-id pub-id-type="pmid">21593588</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name></person-group><article-title>Role of the transcriptional coactivators YAP/TAZ in liver cancer</article-title><source>Curr Opin Cell Biol</source><year>2019</year><volume>61</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2019.07.006</pub-id><pub-id pub-id-type="pmid">31387016</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zhang S, Zhou D. Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr Opin Cell Biol. 2019;61:64&#x02013;71.<pub-id pub-id-type="pmid">31387016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Tumaneng</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP)</article-title><source>Genes Dev</source><year>2010</year><volume>24</volume><fpage>72</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1101/gad.1843810</pub-id><pub-id pub-id-type="pmid">20048001</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 2010;24:72&#x02013;85.<pub-id pub-id-type="pmid">20048001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>AN</given-names></name><name><surname>Curtis</surname><given-names>SJ</given-names></name><name><surname>Fillmore</surname><given-names>CM</given-names></name><name><surname>Rowbotham</surname><given-names>SP</given-names></name><name><surname>Mohseni</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>DE</given-names></name><name><surname>Beede</surname><given-names>AM</given-names></name><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Sinkevicius</surname><given-names>KW</given-names></name><name><surname>Walton</surname><given-names>ZE</given-names></name><etal/></person-group><article-title>Tumor-propagating cells and yap/Taz activity contribute to lung tumor progression and metastasis</article-title><source>EMBO J</source><year>2014</year><volume>33</volume><fpage>468</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1002/embj.201386082</pub-id><pub-id pub-id-type="pmid">24497554</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, et al. Tumor-propagating cells and yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 2014;33:468&#x02013;81.<pub-id pub-id-type="pmid">24497554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Ryu</surname><given-names>KJ</given-names></name><name><surname>Kim</surname><given-names>IK</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Hong</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Downregulation of CHIP promotes ovarian cancer metastasis by inducing snail-mediated epithelial-mesenchymal transition</article-title><source>Mol Oncol</source><year>2019</year><volume>13</volume><fpage>1280</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12485</pub-id><pub-id pub-id-type="pmid">30927556</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Park SM, Park SH, Ryu KJ, Kim IK, Han H, Kim HJ, Kim SH, Hong KS, Kim H, Kim M, et al. Downregulation of CHIP promotes ovarian cancer metastasis by inducing snail-mediated epithelial-mesenchymal transition. Mol Oncol. 2019;13:1280&#x02013;95.<pub-id pub-id-type="pmid">30927556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Chai</surname><given-names>K</given-names></name><name><surname>Ying</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name></person-group><article-title>The role of snail in EMT and tumorigenesis</article-title><source>Curr Cancer Drug Targets</source><year>2013</year><volume>13</volume><fpage>963</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.2174/15680096113136660102</pub-id><pub-id pub-id-type="pmid">24168186</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13:963&#x02013;72.<pub-id pub-id-type="pmid">24168186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WD</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>SZ</given-names></name></person-group><article-title>Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of snail/slug protein translation</article-title><source>Acta Pharmacol Sin</source><year>2019</year><volume>40</volume><fpage>1219</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1038/s41401-019-0240-x</pub-id><pub-id pub-id-type="pmid">31235819</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wang WD, Shang Y, Li Y, Chen SZ. Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of snail/slug protein translation. Acta Pharmacol Sin. 2019;40:1219&#x02013;27.<pub-id pub-id-type="pmid">31235819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name></person-group><article-title>Nodal promotes the migration and invasion of bladder Cancer cells via regulation of snail</article-title><source>J Cancer</source><year>2019</year><volume>10</volume><fpage>1511</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.7150/jca.29205</pub-id><pub-id pub-id-type="pmid">31031861</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Chen W, Jiang T, Mao H, Gao R, Gao X, He Y, Zhang H, Chen Q. Nodal promotes the migration and invasion of bladder Cancer cells via regulation of snail. J Cancer. 2019;10:1511&#x02013;9.<pub-id pub-id-type="pmid">31031861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name></person-group><article-title>Snail is critical for tumor growth and metastasis of ovarian carcinoma</article-title><source>Int J Cancer</source><year>2010</year><volume>126</volume><fpage>2102</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1002/ijc.24901</pub-id><pub-id pub-id-type="pmid">19795442</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Jin H, Yu Y, Zhang T, Zhou X, Zhou J, Jia L, Wu Y, Zhou BP, Feng Y. Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer. 2010;126:2102&#x02013;11.<pub-id pub-id-type="pmid">19795442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Olmeda</surname><given-names>D</given-names></name><name><surname>Jorda</surname><given-names>M</given-names></name><name><surname>Peinado</surname><given-names>H</given-names></name><name><surname>Fabra</surname><given-names>A</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name></person-group><article-title>Snail silencing effectively suppresses tumour growth and invasiveness</article-title><source>Oncogene.</source><year>2007</year><volume>26</volume><fpage>1862</fpage><lpage>1874</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209997</pub-id><pub-id pub-id-type="pmid">17043660</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene. 2007;26:1862&#x02013;74.<pub-id pub-id-type="pmid">17043660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Surowiak</surname><given-names>P</given-names></name><name><surname>Budczies</surname><given-names>J</given-names></name><name><surname>Lanczky</surname><given-names>A</given-names></name></person-group><article-title>Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e82241</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0082241</pub-id><pub-id pub-id-type="pmid">24367507</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241.<pub-id pub-id-type="pmid">24367507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>A</given-names></name><name><surname>Lanczky</surname><given-names>A</given-names></name><name><surname>Menyhart</surname><given-names>O</given-names></name><name><surname>Gyorffy</surname><given-names>B</given-names></name></person-group><article-title>Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>9227</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-27521-y</pub-id><pub-id pub-id-type="pmid">29907753</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8:9227.<pub-id pub-id-type="pmid">29907753</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Krell</surname><given-names>J</given-names></name><name><surname>Stebbing</surname><given-names>J</given-names></name><name><surname>Frampton</surname><given-names>AE</given-names></name><name><surname>Carissimi</surname><given-names>C</given-names></name><name><surname>Harding</surname><given-names>V</given-names></name><name><surname>De Giorgio</surname><given-names>A</given-names></name><name><surname>Fulci</surname><given-names>V</given-names></name><name><surname>Macino</surname><given-names>G</given-names></name><name><surname>Colombo</surname><given-names>T</given-names></name><name><surname>Castellano</surname><given-names>L</given-names></name></person-group><article-title>The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>Suppl 1</issue><fpage>S15</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60330-0</pub-id><pub-id pub-id-type="pmid">26312837</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Krell J, Stebbing J, Frampton AE, Carissimi C, Harding V, De Giorgio A, Fulci V, Macino G, Colombo T, Castellano L. The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network. Lancet. 2015;385(Suppl 1):S15.<pub-id pub-id-type="pmid">26312837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Simeone</surname><given-names>P</given-names></name><name><surname>Trerotola</surname><given-names>M</given-names></name><name><surname>Franck</surname><given-names>J</given-names></name><name><surname>Cardon</surname><given-names>T</given-names></name><name><surname>Marchisio</surname><given-names>M</given-names></name><name><surname>Fournier</surname><given-names>I</given-names></name><name><surname>Salzet</surname><given-names>M</given-names></name><name><surname>Maffia</surname><given-names>M</given-names></name><name><surname>Vergara</surname><given-names>D</given-names></name></person-group><article-title>The multiverse nature of epithelial to mesenchymal transition</article-title><source>Semin Cancer Biol</source><year>2019</year><volume>58</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2018.11.004</pub-id><pub-id pub-id-type="pmid">30453041</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Simeone P, Trerotola M, Franck J, Cardon T, Marchisio M, Fournier I, Salzet M, Maffia M, Vergara D. The multiverse nature of epithelial to mesenchymal transition. Semin Cancer Biol. 2019;58:1&#x02013;10.<pub-id pub-id-type="pmid">30453041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>K</given-names></name><name><surname>Hyun</surname><given-names>J</given-names></name><name><surname>Premont</surname><given-names>RT</given-names></name><name><surname>Choi</surname><given-names>SS</given-names></name><name><surname>Michelotti</surname><given-names>GA</given-names></name><name><surname>Swiderska-Syn</surname><given-names>M</given-names></name><name><surname>Dalton</surname><given-names>GD</given-names></name><name><surname>Thelen</surname><given-names>E</given-names></name><name><surname>Rizi</surname><given-names>BS</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Diehl</surname><given-names>AM</given-names></name></person-group><article-title>Hedgehog-YAP signaling pathway regulates Glutaminolysis to control activation of hepatic stellate cells</article-title><source>Gastroenterology</source><year>2018</year><volume>154</volume><fpage>1465</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.12.022</pub-id><pub-id pub-id-type="pmid">29305935</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska-Syn M, Dalton GD, Thelen E, Rizi BS, Jung Y, Diehl AM. Hedgehog-YAP signaling pathway regulates Glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. 2018;154:1465&#x02013;79.<pub-id pub-id-type="pmid">29305935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Skoulidis</surname><given-names>F</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name></person-group><article-title>Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy</article-title><source>Nat Rev Cancer</source><year>2019</year><volume>19</volume><fpage>495</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0179-8</pub-id><pub-id pub-id-type="pmid">31406302</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495&#x02013;509.<pub-id pub-id-type="pmid">31406302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321:1926&#x02013;7.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Ismail HF, Didari T, Khan F, Niaz K, Mojtahedzadeh M, Abdollahi M. A review on the protective effects of metformin in sepsis-induced organ failure. Cell J. 2020;21:363&#x02013;70.</mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16:1695&#x02013;700.</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Ben SI, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont&#x000a0;M, Bertolotto C, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70:2465&#x02013;75.</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Steinberg GR, Carling D. AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov. 2019;18:527&#x02013;51.</mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Gebert L, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20:21&#x02013;37.</mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Hu J, Wu X, Yang C, Rashid K, Ma C, Hu M, Ding Q, Jiang H. Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C. Cancer Med. 2019.</mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Xuan YW, Liao M, Zhai WL, Peng LJ, Tang Y. MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. Eur Rev Med Pharmacol Sci. 2019;23:8411&#x02013;21.</mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Bolandghamat PZ, Nourbakhsh M, Mousavizadeh K, Madjd Z, Ghorbanhosseini SS, Abdolvahabi Z, Hesari Z, Mobaser SE. Up-regulation of miR-381 inhibits NAD+ salvage pathway and promotes apoptosis in breast cancer cells. EXCLI J. 2019;18:683&#x02013;96.</mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Yi D, Xu L, Wang R, Lu X, Sang J. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int. 2019;43:12&#x02013;21.</mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211&#x02013;26.</mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20:211&#x02013;26.</mixed-citation></ref></ref-list></back></article>